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ABSTRACT
Surgical repair of torn tendons is a common orthopaedic procedure in the United
States, with nearly 400,000 repairs occurring annually. Despite improvements in surgical
techniques used to re-attach the tendon to its boney insertion, clinically successful
outcomes amongst patients are variable and re-tear rates can be exceedingly high. The use
of stem cells as an adjunct to surgical repair to aid in improving tendon healing and repair
strength has gained much interest amongst the clinical community. Accordingly, many
investigators have begun examining the ability of stem cells to differentiate into tenocytes
using various methodologies including the application of growth factors and mechanical
cues. We hypothesized that the differentiation of adipose derived stem cells (ADSCs)
into tenocytes could be achieved via the application of soluble BMP-12, a growth factor
believed to be involved in tenogenesis and which has exhibited the ability to induce neotendon formation following ectopic delivery in rats. Furthermore, we believed that the
application of cyclic tensile strain, in addition to the application of BMP-12, would
enhance tenogenic differentiation. First, based on this hypothesis, we performed in vitro
studies to determine the ideal differentiation conditions to obtain a tenocytes-like
phenotype. Because there is no one specific marker for tenocytes, an array of markers
was used to capture the profile of a tenocytes, which includes scleraxis, tenomodulin,
collagen I and collagen III. Results showed increased tenocytes-like phenotype in ADSCs
differentiated statically for 7 days on monolayer. Using these results, an animal study was
performed on the Achilles tendon of male Lewis rats (n=60) to determine the effects of
BMP-12 differentiated ADSCs on injured tendons. ADSCs were either differentiated
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with BMP-12 or cultured in control medium at the optimal conditions and then seeded
onto Conexa™ scaffolds for three days. At the three day mark, surgeons from the
Steadman Hawkins Clinic of the Carolinas induced a window transection in the Achilles
tendon approximately 2mm x 6 mm and mended the injury with a scaffold either seeded
with no cells (n=20), undifferentiated ADSCs (n=20), or BMP-12 differentiated stem
cells (n=20). The healthy, contralateral leg was used as a positive control. The animals
were sacrificed at 7 weeks and the injured Achilles tendons were acquired for molecular
(n=6), histological (n=4), and mechanical analysis (n=10). The same procedure and
analyses were performed on the contralateral tendons. Results show that autologous cellseeded scaffolds are good candidates for repair of tendon injuries.
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CHAPTER ONE
LITERATURE REVIEW
1. Literature Review
1.1.

Shoulder Anatomy

The shoulder is comprised of two main bones, the humerus and the scapula,
which come together at the humeral head of the humerus and the glenoid located on the
end of the scapula, forming the glenohumeral joint. Articular cartilage, which is located
on the humeral head, works to reduce the friction between these two bones, allowing it to
act as a flexible ball-and-socket joint. The scapula also extends over the joint forming a
roof-like structure called the acromion, which plays a role in tendon injury, as mentioned
later. In order to help stabilize the humeral head within the glenohumeral joint, there is a
small ring of fibrous cartilage, which surrounds the glenoid. This region is referred to as
the labrum. However, this region needs more support in order to sustain elevation of the
arm, as well as rotation of the arm, which is achieved by four muscles and their tendon
insertions into the humeral head called the rotator cuff. The rotator cuff is comprised of
the supraspinatus muscle and tendon, infraspinatus muscle and tendon, subscapularis
muscle and tendon, and the teres minor muscle and tendon, which can be seen in Figure
1.1 below [1].
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Figure 1.1. A) Anatomy of the rotator cuff (posterior view): a) supraspinatus tendon, b)
infraspinatus tendon, c) teres minor tendon, d) greater tuberosity, e) acromion, f)
infraspinatus muscle, and g) teres minor muscle. B) Anatomy of the rotator cuff (anterior
view): a) supraspinatus tendon, b) subscapularis tendon, c) long head of biceps brachii
tendon, d) long head of biceps brachii tendon sheath, e) greater tuberosity of the
humerus, f) acromion, g) coracoid, h) supraspinatus muscle, and i) subscapularis muscle
These muscles attach onto the scapula and extend around the joint to insert into
the humeral head, providing stability to the joint. Prior to insertion, however, these
tendons fuse approximately ½” to ¾” from the humeral head, as can be seen below in
Figure 1.2.
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Figure 1.2. Fusion of the rotator cuff tendons prior to insertion into the humeral head.
SC= Subscapularis, SP = Supraspinatus, IS = Infraspinatus, TM = Teres Minor.
Each muscle of the rotator cuff is responsible for a specific function within this
region. The supraspinatus originates on the Supraspinatus Fossa of the scapula and inserts
into the greater tuberosity of the humerus, allowing it to help adduct the humerus and
stabilize the head of the humerus within the glenohumeral joint, or glenoid cavity.
Secondly is the infraspinatus tendon, which originates on the Infraspinatus Fossa of
scapula and inserts onto the greater tuberosity of the humerus, allowing it to help laterally
rotate, adduct and extend the shoulder joint, in addition to help stabilize the humeral head
within the glenohumeral joint. Thirdly is the teres minor, which originate from the
superior half of the lateral border of the scapula, but also inserts in the same region as the
infraspinatus, providing the same functions. Lastly is the subscapularis, which originates
on the subscapular fossa of the shoulder and insert into the lesser tuberosity of the
humeral head. This placement around the rotator cuff allows for medial rotation of the
shoulder joint and stabilization of the humerus in the joint [2].
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1.2.

Tendon Anatomy

Despite the complex structure of the rotator cuff working to support the humerus
and protect the surrounding regions from damage, primary disorders in and around
tendons arising from overuse, generically termed tendinopathies, and are responsible for
a large portion of morbidity among individuals today. Tendons are a specialized form of
fibrous connective tissue within a body that are organized to resist tensile forces. Their
three main roles within the body are to stabilize the joint, to transmit mechanical forces
from skeletal muscle to bone, and to act as shock absorbers to limit muscle damage [3].
Tendons can be found in a variety of forms, including rounded cords, strap-like bands, or
flattened ribbons, and when healthy, appear intensely white. Structurally, they are
composed of primary (fibers), secondary (fascicles), and tertiary collagen fibril bundles
wrapped in endotenon, as shown in Figure 1.3 [4]. In order for these fibrils to form,
soluble tropocollagen molecules must cross-link the insoluble collagen molecules. These
bundles are in turn wrapped in epitenon, forming the actual tendon, and again in
paratenon in most cases [4]. The paratenon is a layer of thin tissue composed of both
collagen I and III, and an inner lining of fluid rich in mucopolysaccharides that provide
lubrication, prevent friction, and protect the tendon [5].
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Figure 1.3. Biological structure of a healthy tendon.

The cellular composition of tendons is approximately 90-95% tenoblasts and
tenocytes, and 5-10% chondrocytes at the bone attachment and insertion sites, synovial
cells found within the tendon sheath, and lastly, vascular cells, such as capillary
endothelial cells and arteriole smooth muscle cells found passing through the endotenon
and epitenon (5-10%) [4,6]. Tenoblasts are immature tenocytes. As tenoblasts age into
tenocytes, their morphology changes from spindle-shaped containing multiple
cytoplasmic organelles to condone their high metabolic activity, into more elongated cells
characterized by a lower nucleus-to-cytoplasm ratio with decreased metabolic activity.
Oxygen consumption in tendons, compared to skeletal muscle, is 7.5 times lower [7].
Due to a low metabolic rate, tendons undergo slow healing after injury [8]. Not only are
tenocytes in control of energy generation, they also synthesize collagen and the entire
extracellular matrix (EMC). The ECM is composed of proteoglycans, such as decorin,
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versican, and lumican, glycosaminoglycan (GAG), glycoproteins, such as tenascin and
elastin, and other small molecules [9]. The tenocytes and tenoblasts position themselves
longitudinally between the collagen fibres [8]. The structural composition of the
extracellular matrix of tendon includes collagen, predominately type I, but also small
amount of II, III, IV and V, which accounts for 65-80% of tendons dry weight, and
elastin, approximately 2% of the dry weight. However, the dry weight only comprises
30% of the total tendon mass, with water within the ground substance accounting for the
remaining 70%. These substances allow tendons to possess their characteristic
mechanical properties, with collagen type I providing tendons the ability to withstand
high loads and elastin providing the flexibility and elastic properties.

1.3.

Tendon disorders

Tendon disorders are a large portion of the cases rheumatologists and orthopaedic
surgeons deal with on a day-to-day basis, especially in the ageing, sedentary population.
Such injuries also prove to be disabling for several months even with appropriate
management [10]. On average, lesion presence in cadavers is equal to 80% in specimens
of patients over 80 years, 50% in specimens of patients over 70 years, 30% in specimens
of patients over 60 years, and 6% in specimens from cadavers of patients aged less than
60 years [11]. This is partially due to the decrease in tendon blood flow and changes in
proteoglycan and collagen composition within the tendon that occurs with increased
aging [12]. Because tendons disorders are so prevalent, over 400,000 rotator cuff repair

6

surgeries occur annually in the United States alone [13].
Injuries within a tendon can be classified as acute, such as tendon rupture, or
chronic, and are caused by either intrinsic or extrinsic factors, or a combination of the
two. Intrinsic factors are more pathological and many studies have been done to observe
these effects. Holmes and Lin observed the effects of multiple endocrine-metabolic
diseases, such as diabetes mellitus, obesity, and hypertension, among others, on tendons
[14]. Diabetes mellitus was found to have a positive correlation with the development of
tendinopathy in men younger than 44, hypertension was associated with tendinopathy in
women, and obesity had a positive correlation within males and females. For example,
elevated glucose levels results in the accumulation of advanced glycation end products
(AGEs) in tendon tissue, causing the tendons to become stiffer, despite their ability to
withstand an increase in load and tensile stress compared to non-glycated tendons
[15,16]. High amounts of AGEs also cause collagen fibrils to fuse together, resulting in
an increased diameter. Lastly, connective tissue growth factor in fibroblasts is also upregulated by the presences of AGEs, promoting the formation of fibrosis in diabetic
patients over time [17,18,19]. Extrinsic factors are classified more commonly as overuse
injuries or fatigue, such as excessive distance while running or erroneous running
technique [20]. During vigorous physical training, excessive loading of tendons has been
shown to be the main pathological stimulus for tendon degeneration. In the presence of
intrinsic factors, tendinopathy development is more likely to occur due to excessive
loading. Tendons respond to repetitive loading that occurs beyond the physical threshold
of the tendon by either degeneration of their body, inflammation of their sheath, or a
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combination of both [21]. In general, extrinsic risk factors predominate in acute cases,
however when chronic trauma occurs, intrinsic factors play more of a role [8]. Despite
these findings, the etiology of tendinopathy is unclear, although many causes have been
hypothesized.
Mechanisms such as impaired apoptosis, bone spurs within the acromion
reducing the area for the supraspinatus (2), osteophytes (4), ischemic damage, hypoxia,
oxidative stress, hyperthermia, inflammatory mediators, and matrix metalloproteinase
imbalance [3], have all been associated with tendon degeneration [4]. However, a large
emphasis is placed on inflammatory mediators and matrix metalloproteinases (MMPs)
because excessive overuse of tenocytes has shown to elicit their expression in vitro,
suggesting this may trigger an increase in the photolytic activity within the tendon. This
is exacerbated by damage to tendon fibers because MMP output is mediated by strain on
the tendon cells through the cytoskeleton, however when the tendon fibers are damaged,
the cells are released from strain regulation and an increase in collagenase activity and
matrix degradation occurs [6]. Degenerative tendinopathy is the most common
histological finding in cases of spontaneous tendon rupture, a form of acute injury. In a
study analyzing 891 spontaneous tendon ruptures, 97% or 865 specimens showed signs
of degenerative changes, while only 34% or 149 of 445 specimens showed degenerative
changes in the control [22]. Following an acute injury, the body tries to mend the region
and this occurs in three overlapping phases, as described later.
Over the past 15 years, molecular pathology of tendinopathy is becoming more
defined and increasing our understanding of the issue. Important features to mention are
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that an increase of messenger RNA of collagen types I and III, fibronectin, tenascin C,
aggrecan and biglycan, as well as type III collagen proteins, are found in the injured
tendon matrix. Despite the increase in collagen type I expression, injured tendons contain
a higher percentage of collagen type III compared to normal tendons which contain a
higher percentage of collagen type I. In addition, ruptured tendons show increased levels
of MMP1, MMP9, MMP19, MMP25, and tissue inhibitor of metalloproteinase 1
(TIMP1), and decreased levels of expression of MMP3, MMP7, TIMP2, TIMP3, and
TIMP4 [6].
Within the shoulder rotator cuff model, tendon tears are most prevalent in the
supraspinatus tendon near its bony insertion onto the humeral tuberosity. This insertion is
broad, continuous, interwoven, and multilayered [23]. As tears in the supraspinatus
widen, they begin to cause tearing in the infraspinatus tendon as well because these two
tendons fuse 1.5 cm proximal to their insertions, as previously mention and as shown in
Figure 1.1 [24]. What is important to know anatomically about this insertion region is
that it is composed of four transition zones. The first zone, or tendon proper, is composed
primarily of type I collagen and small amounts of decorin. The second zone, or
fibrocartilage, is composed of primarily types II and III collagen, with small amounts of
type I, IX, and X collagen. The third zone, or mineralized fibrocartilage, consists of type
II collagen, in addition to type X collagen and aggrecan. The fourth zone is bone, which
contains a higher mineral content and large quantities of type I collagen. In order for this
attachment region to possess its unique properties, it must contain this gradient of mineral
content and collagen fibre orientation that allows the tendon to withstand both tensile and
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compressive forces [24]. However, when injury occurs, type III collagen percentages
increase and despite the fact that collagen type III is present in normal tendons
throughout the endotendon and epitendon, it can have detrimental effects when it
becomes intercalated with collagen type I fibrils at the insertion sites of highly stressed
tendons, like the supraspinatus. This is mainly due to the fact that collagen type III fibrils
are smaller and less organized, which ultimately affects the mechanical strength of the
tendon [6].

1.4.

Tendon Healing

When injury to the tendon occurs, the body tries to repair the damage through the
three phases of healing. The first phase consists of the inflammatory response, which is
characterized by hematoma formation, fibrin deposition, inflammatory cells, fibroblasts,
and the beginning of elastin and collagen fibrillogenesis. The second phase is
proliferation, which is characterized by angiogenesis and fibroblast proliferation with
collagen fibers displayed in random arrangement. Lastly, remodeling beings to restore
normal vascularization, tendon crimping, collagen and elastic fiber orientation [25].
However, the overall structure, composition, and organization of the unmineralized
fibrocartilage to mineralized fibrocartilage are not reestablished. This may be due to a
variety of reasons, including inflammatory cells present at the tendon-bone interface,
which precipitates scar formation in the region, or a potential lack of undifferentiated
stem cells present in the healing region [26]. If a tendon were to rupture, surgical repair
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would be necessary to promote healing. Despite these processes, the biomechanical and
the biochemical properties of healed tendon never match those of intact tendon [4].
Bruns et. al. have shown that after 12 months of spontaneous healing, transected sheep
Achilles tendon had a rupture force only 56.7% of the normal rupture force [27]. In
addition, failed healing or recurrent tears of the rotator cuff after repair of large or
massive tears is a major complication, with structure failure rates acknowledged to be
13% to 94% [26]. In order to enhance tendon healing to bone, a graft is needed to bridge
the injury site during surgical repair. This provides three possibilities: 1) Allografts, 2)
Autografts, and 3) Xenografts. However, each of these options is not ideal, typically. If
rotator cuff disease is present, causing the initial tendon tear, then it is highly likely that
the other tendons within the cuff are also diseased. Therefore, an allograft would not be
ideal because the new graft would not be strong mechanically in comparison to a healthy
tendon. Therefore, the autograph has a high potential to rupture than a healthy tendon.
Secondly are autografts, however if foreign cell markers are not removed appropriately,
they can cause an immune response and undergo rejection from the host. Lastly are
xenografts, but the FDA has not approved them for use in tendons. Tissue-engineering
studies, however, have shown that the insertion of stem cells into a repair region appear
to be not only safe, but when introduced in conjunction with a scaffold and growth
factors, actually enhances rotator cuff healing [28,29,30]. Improvement in the rotator cuff
due to stem cells is thought to be because stem cells have a high intrinsic capacity for
regeneration, which tendon cells, or tenocytes, do not possess. Therefore, the stem cells
can produce tissue that is similar to the pre-injured tissue, however these results are
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variable depending on the treatment [31].
The use of stem cells to enhance tendon healing is being explored more everyday.
There are three main types of stem cells within the body used for tendon repairs, which
include bone marrow derived stem cells (BMSCs), originating in the bone marrow,
embryonic stem cells (ESCs), residing within an embryo, and lastly, Mesenchymal stem
cells (MSCs) which can be obtained from adipose tissue. Multiple studies have been
performed to observe their effects on tendon healing. In a study done on 141 racehorses
that obtained an overstrain injury in their flexor tendons, it was found that the injection of
MSCs into the region significantly reduced the re-injury rate in the tendon two years after
surgery [32]. In another study dealing with tendon defects in the rat tendon, it was seen
that the introduction of BM-MSCs tagged with BMP-12 actually increased cell-number
elongation and alignment along the tensile axis. Greater matrix deposition was also seen,
in addition to elevated expression of tendon markers [33]. Despite the ability BMSCs and
ESCs have to improve tendon healing, it is hard to obtain these cell types. Cell removal
must be done through an invasive procedure. However, Mesenchymal adipose derived
stem cells have been shown to not only possess an extensive capacity to proliferate, but to
also differentiate into multiple lineages. According to a study done by Zuk, these cells
were capable of differentiating into chondrocytes, osteocytes, and adipocytes [34].
However, all multipotent stem cells have this ability to differentiate. What makes
adipose derived Mesenchymal stem cells so unique is that they can be removed
minimally invasively through lipectomy or liposuction. This method also provides large
quantities of the stem cells, so cell proliferation is not necessarily needed after the cells

12

are acquired. Due to these cells’ ability to differentiate, and tenocytes limited intrinsic
capacity to regenerate, researchers have been examining the effects of the addition of
cytokines either into the region receiving stem cell therapy, or differentiating the stem
cells using cytokines prior to their insertion into the tendon, to determine if improved
healing is occurring. Because there is no one specific cell marker for tenocytes, an array
of markers characteristic of tendons is used to analysis the healing of tendons through
processes such as rt-PCR and Western Blot. Some of these markers include scleraxis,
which is a transcription factor, tenomodulin, which is a type II transmembrane
glycoprotein, and collagen I and III, which are connective tissue proteins [35]. Certain
cytokines, which are used for differentiation are of specific interest to researchers due to
their increased expression levels of tenocyte markers during the repair stage of healing.
During this stage, fibroblasts become activated and begin excreting basic fibroblast
growth factor (bFGF), insulin-like growth factor-1 (IGF-1), platelet derived growth
factor-β (PDGF-β), vascular endothelial growth factor (VEGF), and bone morphogenic
protein -12 (BMP-12), BMP-13, and BMP-14. PDGF-β has shown to enhance tendon
healing due to the production of type I collagen level, however IGF-1 and bFGF have
adverse effects on tendon healing. IGF-1 has been noted to exert an anabolic effect on
tendon healing, despite its ability to increase collagen synthesis. bFGF increases the level
of collagen III significantly more than collagen I, reducing the mechanical properties of
the tendon [26]. Other studies have shown, nevertheless, that BMP-12 and TGF-β1 are
both capable of differentiating Mesenchymal stem cells into a tenocyte-like phenotype.
[33,36,37,38,39]. In addition, uniaxial dynamic loading placed on the cells for 2hr/day
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during differentiation has shown to up-regulate scleraxis and collagen I expression,
compared to cells cultures on monolayer [39]. It was hypothesized that these results were
seen because the uniaxial loading stimulates tenoblast activities, such as fibroblast
proliferation and collagen synthesis and alignment [40,41,42].

1.5.

Project Objective

Therefore, because adipose derived Mesenchymal stem cells have a high capacity
for proliferation and differentiation, and that they are easily accessible, I wanted to
develop a scaffold seeded in autologous adipose derived stem cells differentiated into
tenocytes that could be used to bridge the tendon injury site during repair to further
improve tendon healing after repair. This would not only help reestablish a healthy
tenocyte presence in the region where damaged tenocytes have a lower intrinsic capacity
for regeneration, but it would also provide a large source of collagen I to mechanically restrengthen the tendon by reestablishing the collagen I:collagen III ratio found in healthy
tendons. In order to do this, I had to first determine the ideal differentiation period,
differentiation supplementation concentrations, and differentiation environment
(mechanically and structurally).

1.6.

Animal models

To test the healing effects of the scaffolds, they needed to be tested within an
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animal model. Over the years animal models have contributed to our understanding of the
physiology, pathology, and biomechanics of tendons. Due to the fact that I am more
interested in seeing the healing effects of the scaffold in terms of tendon repair and not
just the rotator cuff model, it provides a little more flexibility for choosing the animal
model. However, as a comparison, I will explain some models used for rotator cuff
repair. First, are the rat models, which were developed by Soslowsky et al. This model is
considered to be most similar to the human when respect to the bony anatomy and
physiology [43].
As mentioned earlier, the acromion is a region of the clavicle that extends over the
glenohumeral joint, creating a roof. This structure is also found in the rat model. The
presence of this arch and the interaction it has with the supraspinatus tendon is similar to
that in a human, making this a good model to study the healing mechanisms and
regenerative strategies for acute tendon-to-bone repair [44,45,46,47]. In addition, rats are
lost cost, easy to manage, and allow for a large sample size.
Restrictions of the rat model include the inability to use stand-of-care repair
techniques similar to those used in the human rotator cuff due to the small size of the rat
shoulder tendons. Also, the rat and other animal models, undergo healing of the rotator
cuff injury and scar tissue formation in the absence of treatment, which hinders the
discrimination spontaneous healing and healing as a result of manipulation. Spontaneous
healing does not occur in the human rotator cuff.
Large animal models are also an option, which includes animals such as dogs,
rabbits, and sheep. These animals are different compared to humans because the
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acromion is either extremely reduced or nonexistent [48,49]. In addition, the soft tissue
anatomy of the shoulder is different in large animal models compared to humans because
the tendons are highly articular, extremely aligned, and not interdigitated. This lessens
their ability to retain sutures, like soft-tissue found in humans. These models are not used
frequently to study chronic rotator cuff repair because after 6 weeks, injured tendons
begin to retract and the muscles in the region atrophy and stiffen [50] However, the main
drawback of large animal models are that their tendons are prone to re-tear, making them
less effecting when studying the treatment effects of biological supplements. These
supplements ultimately work to instead influence star tissue formation in the gap between
the bone and the retracted tendon. In addition, they require more money and space to
maintain, and due to their size, may limit the sample sizes attainable.
Therefore, large animal models were ruled out and rats were chosen for the
animal study. Because the size of the rotator cuff tendons in rats are so small, the Achilles
tendon was used to examine the effects of implanted scaffold containing with no cells,
undifferentiated adipose derived stem cells, or BMP-12 differentiated adipose derived
stem cells. In addition to the accessibility of the Achilles tendon, it has also been used in
many studies to examine the effects of tendon repair [51].
Conexa decellularized dermis scaffold used was chosen based on its availability
and FDA approval for use in tendons. However, there are many scaffolds available for
purchase that are approved for use by the FDA for implantation into humans. Some
categories of these include pericardial xenografts (OrthoADAPT), synthetic scaffolds
(Lars® ligament, Polt-tape®, etc.) dermal allografts (Graftjacket and Allopatch), and
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small intestinal submucosa xenografts (CuffPatch, Restore graft, etc.) [51].
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CHAPTER TWO
AIM 1: OPTIMIZING THE DIFFERENTIATION OF LEWIS RAT ADIPOSE
DERIVED STEM CELLS TOWARDS A TENOCYTE-LIKE PHENOTYPE

2. AIM 1
2.1.

Introduction

2.1.1. Project Rational

Soft tissue tears are a very common occurrence in the Unites States. Despite how
common surgical repair of these regions is, healing of tendon to bone is highly
unpredictable due. For example, clinical studies have shown in the rotator cuff
radiographic failures at the repair region in any where from 30-95% of patients two years
after surgery, depending on the size and chronicity of the tear, the presence of fatty
infiltration, and general age and health status of the patient. This is not only the case for
the rotator cuff, however. The highest incidences of failed healing occur in the
supraspinatus tendon of the rotator cuff, Achilles tendon of the leg, Patella tendon of the
knee, and the lateral and medial tendon in the elbow [1, 2, 3]. Due to this, a graft is
needed to help reduce the instances of retear, providing three possibilities: autographs,
allografts, and xenografts. For example, in the rotator cuff, autografts are not ideal
because if rotator cuff disease is present in the cuff causing the initial tendon tear, then it
is highly likely that the surrounding tendons are also diseased and you would not want to
use them as a potential graft source. Secondly are allografts, however you run the risk of
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rejection due to foreign cell markers. Lastly are xenografts, but the FDA has not
approved their use in the rotator cuff. Tissue engineering studies, however, have shown
that the injection of stem cells into the region of repair in conjunction with growth factors
and a scaffold enhances rotator cuff healing [4,5,6]. Because tendons have a limited
intrinsic capacity for regeneration, I wanted to use the regenerative medicine approach to
construct a scaffold seeded in autologous adipose derived stem cells differentiated into
tenocytes, which could be implanted during surgical repair. The goal would be to further
enhance healing after surgery and hopefully reduce surgical failure rates by helping
replenish the damaged tenocytes and providing a source of collagen I to the region to
help mechanically re-strengthen the tendon.
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2.2.

Materials

Recombinant Mouse GDF-7/BMP-12 (779-G7) was purchased from R&D Systems.
Recombinant Human BMP-12/GDF-7 (4572-100) was purchased from BioVision.
Recombinant Human TGF-β1 (100-21) was purchased from PeproTech. 10 µl protease
inhibitor cocktail (P-8340), Oil Red-O stain (O0625), and Ascorbate-2-phosphate
(A8960) were purchased from Sigma-Aldrich Corporation. Anti-Collagen I antibody
(ab34710), Anti-Collagen III antibody (ab7778), and Anti-SCXA antibody diluted
(ab58655) were purchased from Abcam. Tenomodulin antibody (sc-98875) was
purchased from Santa Cruz Biotech, Incorporation. QuantiTect SYBR Green PCR Kit
(204143), RNeasy Fibrous Tissue Mini Kit (74704), TURBO DNA-free™ Kit
(AM1907M), RETROscript® First Strand Synthesis Kit (AM1720), and the Rotor-Gene
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Q (9001863) were purchased from Qiagen. BioFlex–Collagen Type I coated 6-well plates
(BF-3001C-Each) were purchased from FlexCell International Corporation. BCA protein
kits (23225) were purchased from Pierce Biotech. BM Chemiluminescence Western
Blotting Kit (Mouse/Rabbit) (11520789001) was purchased from Roche Applied Science.
LIVE/DEAD® Viability/Cytotoxicity Assay Kit (L-3224) and Goat anti-Mouse IgG (11033) were purchased from Invitrogen. NanoDrop 2000 was purchased from
ThermoScientific. Ready gels 4-15% Tris-Acl 50uL, 10 wells (161-115B) were purchase
from Biorad. Alcian Blue (A3157) and Alizarin Res S 1% (s2007) were purchase from
Poly Scientific. Fetal Bovine Serum Premium was purchased from Atlanta Biologicals
(S11150). DMEM containing 1g/L glucose (MT-10-014-CM), 1X Phosphate Buffered
Saline without Ca2+ and Mg+ (MT-20-031-CV), BSA from Rockland – fraction V
(NC9418785), Dexamethasone (0.5g) (ICN19456190), β-glycerophosphate
(ICN15724150), and Antibiotic/Antimycotic (MT-30-004-Cl) were purchased from
Fisher Scientific. Collagenase type I was purchased from Worthington Biochemical
Corporation (XOM12195 CLS1). Anti-Prolyl 4-Hydroxylase β clone primary antibody
(MAB2073MI) and Bioseparations Centrifugal Filter Device Microcon YM-3 (42404)
were purchased from Millipore. 0.5mM isobutyl-methylxanthine (100000-554), Insulin
(IC15504410), and Indomethacin (80055-534) were purchased from VWR Scientific.
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2.3.

Methods

2.3.1. Animal Model: Lewis Rats

Lewis rats were the ideal animal species for this project because they are
syngeneic, or genetically identical, allowing cells harvested from one rat to be
transplanted into another without rejection. This allows cells isolated in AIM 1 to be used
for AIM 2. The Achilles tendon was chosen for the animal study in AIM 2 due to its
accessibility and relatively larger size compared to the supraspinatus tendon of the rotator
cuff.

2.3.2. Reconstitution of BMP-12 and TGF- β1

BMP-12 and TGF- β1 were reconstituted before use. Differentiated cells from
Study 1 were cultured in 50ng/mL Recombinant Human BMP-12 (BioVision, 4572-100)
reconstituted to a concentration of 0.1 mg/mL in water containing BSA (50µg BSA per
1µg of protein). After Study 1, all studies used Recombinant Mouse GDF-7/BMP-12
(R&D Systems, 779-G7) reconstituted at 100µg/mL in sterile 4mM HCL containing at
least 0.1% human or bovine serum albumin. Recombinant Human TGF-β1 (PeproTech,
100-21) was reconstituted at .5mg/mL in 10mM Citric Acid containing 0.1% BSA and
then adjusted to pH 3.0.
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2.3.3. Lewis rat tissue collection

Shoulder tissue samples were collected from Lewis rats for cell culture and
molecular analysis. All arms were first skinned to expose the tendons. Shoulder
supraspinatus and infraspinatus tendon samples were excised from the muscle and bone,
combined, and placed in either warm control media for tenocyte isolation, as described in
Table 2.2, for a maximum of two hours, or in RNAlater for tRNA isolation until isolation
could take place. The legs extracted for mechanical testing were stripped of the skin to
expose the tendon and muscle, and then the entire leg was extracted from the body
halfway up the muscle belly. The legs were then wrapped in gauze moistened with PBS
and stored at -80°C for future testing. Inguinal adipose tissue was also collected from the
adult rats and placed in warm control media for a maximum of two hours until the
Adipose Derived Stem Cells could be isolated for cell culture and molecular analysis.

2.3.4. Lewis rat tenocyte isolation

Lewis Rat tenocytes were isolated from the supraspinatus and infraspinatus
tendon using the protocol below. These cells were then combined for culture.

1. Make solution:
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a. Collagenase solution: 1% Bovine Serum Albumin (BSA) + 2mg /mL
collagenase type I (Worthington XOM12195 CLS1- >280 U/mg) in 1X
PBS.
2. Tendon tissue was collected into a sterile collection vessel containing pre-warmed
DMEM (1g glucose/liter) +10% FBS + 1% Ab/Am and subsequently transported
to lab within two hours of harvest.
3. In an aseptic cell culture hood, tendon tissue was rinsed once in 20mL of sterile
1x PBS to remove excess blood.
4. The connective tissue surrounding the tendon (peritenon sheath) was carefully
removed with sterile scissors and tweezers.
5. Tendon was minced into approximately 5 x 5 mm pieces/cubes with sterile scalpel
blades in a sterile petri dish (95 x 15 mm).
6. 20mL of sterile filtered collagenase type I (Worthington: 280U/mg) solution was
added and incubated for 192 minutes at 37˚C in a humidified cell culture
incubator at 37oC at 5% CO2 and were agitated every 5-10 minutes.
7. Digests were then filtered through sterile 100µm mesh sieves into sterile 50mL
conical tubes.
8. Samples were then transferred to 15mL conical tubes (two per sample) for
centrifugation (to obtain improved cell pelleting).
9. Centrifuge at 1500 rpm for 10 minutes.
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10. Supernatant was aspirated and cells were re-suspended in fresh media
(DMEM+10% FBS+1% Ab/Am) and were subsequently centrifuged at 1000 rpm
for 5 minutes to wash the cells.
11. Cells were then re-suspended again and plated at a density of ~ 5000 cells/cm2
into T-25 flasks.
12. Undigested samples (sample caught in the mesh filter) were plated in a 6-well
plate with only a drop or two of media to allow the cells to migrate out over time.

Collagenase type I solution was sterile filtered before use. The tendons were kept
in the collagenase solution for a total time of three hours and 12 minutes. The tenocytes
were then cultured in expansion medium, as described below in Table 2.2. The
undigested tendon samples were placed in a six well plate and allowed to culture until
75% confluence was achieved. Isolated tenocytes were used as a positive control for later
RNA studies.

2.3.5. Lewis rat Adipose Derived Stem Cell isolation and culture

Lewis rat Adipose Derived Stem Cells (ADSCs) were isolated from the inguinal
fat pads excised from Lewis rats using the protocol below. Due to their ability to
differentiate into multiple cell types, more specifically tendon cells, and the fact that this
region is easily accessible and can be removed in a non-invasive, non-painful, and nonterminal manner, it was chosen for isolation.
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1. Make solutions:
a. Collagenase solution: 1% Bovine Serum Albumin (BSA) + 2mg/mL
collagenase type I (Worthington XOM12195 CLS1- >280 U/mg) in 1X
PBS.
b. NH4Cl Solution: 0.1mM EDTA + 155mM NH4Cl in 1X PBS.
2. Inguinal adipose tissue collected from adult rats in DMEM (1g glucose/l)
+10%FBS + 1% Ab/Am – collected fat from each rat in separate 15mL conical
tubes filled with 5mL media.
3. Cut adipose tissue into small pieces in a sterile petri dish with scalpel blades and
put into 50mL conical tubes filled with 20mL collagenase (280 U/mg in 60mL to
get 15,000 U total) solution.
4. Incubate the samples for 2 hours at 37˚C under agitation.
5. Shake every 5 to fifteen minutes.
6. Filter samples through 100µm sieves into new 50mL conical tubes to dissociate
any remaining connective tissue.
7. Remaining fat was rinsed twice with control DMEM media (10%FBS +1%
Ab/Am) through a 100µm sieve and then placed into a six well plate with only a
drop of media to allow fat/cell adhesion.
8. Transfer filtered collagenase containing cells to a new 15mL conical tube for
centrifugation (to obtain improved cell pelleting).
9. Centrifuge at 1000 rpm for 5 minutes.
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10. Aspirate supernatant (leave ~2mL collagenase solution to avoid sucking up pellet)
and re-suspend in 5mL NH4Cl solution for 5 minutes at room temperature.
11. Centrifuge at 1000rpm for 10 minutes.
12. Aspirate supernatant (leave ~ 1mL of solution again) and re-suspend in 3mL of
control media (DMEM+10%FBS+1% Ab/Am)
13. Count and plate cells at preferred cell density.

The Collagenase type I solution was sterile filtered before use, as well as the
NH4Cl solution. The fat globules were kept in collagenase solution for a total of two
hours and the cells isolated were cultured in expansion medium, as described below in
Table 2.2. The undigested fat globules were placed in a six well plate with minimal
media until the tissue attached to the surface. Once attached, enough media was added to
the well to cover the tissue. The media was changed every two days until the preferred
confluence was achieved, at which point the cells were frozen down using the protocol
below.

2.3.6. Cell passaging, trypsinization, and freezing

Once the isolated Lewis rat tenocytes and Adipose Derived Stem Cells had been
cultured to the maximum confluence, they were either passaged or frozen down and
placed into liquid nitrogen for future use using the protocols below.

34

CELL PASSAGING
Wash each T-150 flask with 20 mL of DPBS 1X – remove from flask.
1. Repeat.
2. Place 3mL trypsin in each flask and make sure it is spread out evenly over the
cells.
3. Place in incubator for 5 minutes.
4. Tap the bottom of the flask to help cell removal and observe under the microscope
after the 5-minute period.
5. If all are detached, place 10mL of media into each flask.
6. Move the media in each flask into individual 15mL conical tubes.
7. Spin the conical tubes down at 1000 rpm for 5 minutes.
8. Remove media except for 0.5mL.
9. Re-suspend the cells in each conical tube individually.
10. Consolidate the cells into a 50mL conical tube- or however many needed.
11. If volume of media needs to be adjusted, you can spin the cells down again and
re-suspend them in the appropriate media.
12. Count the cells.
13. Aliquot the appropriate amount of cells into new T-150s for expansion.

CELL FREEZING
NOTES & MATERIALS:
1. Typically freeze down approximately 2x106 cells per mL in a cryovial

35

2. Freezing Media A: make in a sterile 15mL conical tube
§

For every 1mL of freezing media A (make a total of 10mL):
o 0.6mL MesenPro Complete Media
o 0.4mL Fetal bovine serum

3. Freezing Media B: make in a sterile 15mL conical tube
§

For every 1mL of freezing media B (make a total of 10mL):
o 0.8mL MesenPro Complete Media
o 0.2mL Dimethylsulfoxide (DMSO)

PROCEDURE:
1.

Rinse cells twice with 1x PBS (without calcium and magnesium), use
approximately 15mL per T-150 flask.

2.

Add ~ 3mL of pre-warmed trypsin/EDTA solution to each T-150 culture
flask and incubate for 5-7 minutes.

3.

Add ~ 10mL of pre-warmed MesenPro Complete media to trypsinized cells
and transfer in sterile 15mL conical tubes.

4.

Spin down cells into a pellet at 1,000 RPM for 5 minutes.

5.

Remove all except 1mL of supernatant and then re-suspend cells by gentle
pipetting.

6.

Combine all cells into one sterile 15mL conical tube.

7.

Count cells and determine the total volume of media needed to yield 4x106
cells/mL.
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8.

Spin down cells, remove all media and re-suspend cells in Freezing Media A
to a density of 4x106 cells/mL.

9.

Add an equivalent volume of Freezing Media B in a drop-wise fashion to
yield a final cell density of 2x106 cells/mL. Mix by gentle pipetting.

10. Aliquot out 1mL of cell suspension into each cryovial.
11. Seal cryovial and place in plastic freezing container and transfer to -80oC
freezer for 24 hours.
12. Following 24 hours at -80oC, transfer cells into liquid nitrogen tank.

2.3.7. Gene Expression Analysis

These protocols were used for all gene expression analyses in AIM 1 and AIM2.
Gloves must be worn at all times when handling tRNA to prevent contamination of the
sample.

tRNA ISOLATION AND DNASE TURBO TREATMENT OF CELLS, SCAFFOLDS,
AND TISSUE
tRNA was isolated from cells, scaffolds, and tissue using the RNeasy Fibrous
Tissue Mini Kit (Qiagen, 74704) with the protocol found below. For each study, three
wells/scaffolds/extracted tissues were pooled to obtain an n= 2 samples. To prevent
tRNA degradation, samples were placed on ice during isolation. It is important to remove
contaminating DNA to prevent it from being amplified in the PCR reaction, which was
done using the TURBO DNA-free™ Kit (Ambion, AM1907M). tRNA samples were
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then stored at -80°C until RNA quantification could be performed using the protocol
found below.

FROM FRESH TISSUE/SCAFFOLDS AND TISSUE/SCAFFOLDS IN RNAlater:
1. Remove scaffolds with cells from well plate using sterile forceps. Do not use
more than 30 mg total weight of sample.
2. Immediately place in liquid nitrogen to snap freeze.
3. Pulverize quickly and add to sterile RNase free 2mL tube.
4. Add 300µL RLT buffer to tube containing pulverized sample.
5. Homogenize for 30 seconds.
6. Add 590µL of RNase-free water to the lysate and then add 10µL of supplied
proteinase K solution and mix thoroughly by pipetting.
7. Incubate at 55oC for 10 minutes.
8. Centrifuge at room temp for 3 minutes at 10,000xg.
9. Pipette only the supernatant into a new 2mL microfuge tube.
10. Add 450µL of 100% ethanol (RNA use only ethanol in flammable cabinet) and
mix well by pipetting. Do not centrifuge.
11. Transfer 700µL of the sample, including any precipitate to an RNeasy mini spin
column placed on a 2mL collection tube.
12. Centrifuge at 10,000xg for 15 seconds at room temp. Discard flow through.
13. Repeat step 11 and 12 for the remainder of the sample. Poole three
scaffolds/extracted tissues to obtain an n=2 samples.
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14. Proceed to step 7A.

FROM CELLS IN MONOLAYER CULTURE IN WELL PLATES:
1. Wash wells three times with PBS (no Ca2+ or Mg2+)
2. Proceed to step 1A below.

FROM CELLS IN RNALATER:
1. Transfer the cells in RNA later to a 50mL tube, and add 3x volume RLT w. βME.
2. Homogenize for 30 seconds.
3. Add EtOH 70% and mix well by vortexing.
4. Proceed to step 4A below.

1A. Add 350µL of RLT buffer (with β-ME: 10µL β-ME per 1mL of RLT) to each
well and scrape with cell scraper.
2A. Transfer to an RNase free 2mL tube and homogenize by passing lysate through a
20 G syringe at least 7 times.
3A. Add 350µL of FRESH 70% EtOh to each tube containing homogenate. Pipette
thoroughly in order to mix well.
4A. Add up to 700µL of homogenate to a spin column with attached 2mL collection
tube.
5A. Centrifuge at 10,000xg for 15 seconds.

39

6A. Repeat until entire volume is spun through column. (n=2 samples)
7A. Discard flow through and re-use collection tube.
8A. Add 700µL RW1 to column and centrifuge at 10,000xg for 15 seconds. Discard
flow through and re-use collection tube.
9A. Add 500µL RPE buffer to column and centrifuge at 10,000xg for 15 seconds.
Discard flow through and re-use collection tube.
10A. Add 500µL RPE buffer to column and centrifuge at 10,000xg for 2 minutes.
Discard flow through and collection tube.
11A. Place columns on new 2mL collection tube and centrifuge at max speed for 1
minute.
12A. Place the spin column on a new 1.5mL RNase-free collection tube, add 40µL
RNase-free water and centrifuge for 1 minute at greater than 10,000 RPM to
elute the RNA.
13A. Add another40µL RNase-free water to the column membrane and centrifuge for
1 minute at greater than 10,000 RPM to elute the RNA.

Place tubes on ice until they can be transported and stored in the -80oC or proceed
to DNase Turbo treatment below to remove contaminating DNA.

14A. Add 8µL of 10X turbo DNase reaction buffer to the 80µL RNA sample and
mix gently by pipetting (this yields a 1X buffer concentration – can adjust this
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depending on your volume, however you always want a 1x buffer in your final
volume).
15A. Add 1µL of DNase I reagent and mix gently by pipetting.
16A. Incubate for 30 minutes at 37 ºC.
17A. Add 8µL of DNase inactivation reagent and mix well by pipetting.
18A. Incubate 5 minutes at RT with occasional mixing every 2 minutes by flicking
the tube with your finger.
19A. Spin at 10,000 g (11,000 rpm) for 1 ½ minutes at 4 ºC, remove ~60µL
supernatant (don’t want to suck up any of the DNA pellet).
20A. Place 60µL into new RNase free 2mL microfuge tube and place on ice until
samples can be transported and stored at -80oC.

tRNA QUANTIFICATION USING THE BIOANALYZER CHIP
For quantification, the chip priming station was cleaned, the electrodes were
decontaminated, and the bioanalyzer was set up. The software used for quantification was
the 2100 Expert Software. All tasks were performed according to the Agilent RNA 6000
Nano Kit Guide [1]. While quantifying the samples, they were placed on ice to prevent
degradation of the tRNA.

EQUIPMENT:
1. RNA 6000 Nano Assay Kit (Agilent Technologies, 5067-1511) with Agilent
RNA 6000 Nano Chips and Nano Reagents (ladder, dye concentrate, marker, and
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gel matrix)
2. Chip Priming station
3. IKA vortex mixer (Model MS2-S8/MS2-S9)
4. 16-pin bayonet electrode cartridge
5. PCR machine/heating block set to 70 0C
6. RNAseZap (Ambion, Inc., 9780)
7. RNase-free water
8. Microcentrifuge
9. Microcentrifuge tubes
10. Pipette and tips
11. Ice

TRNA QUANTIFICATION USING THE NANODROP 2000
tRNA concentration quantification was also performed using the NanoDrop 2000
(ThermoScientific) and the protocol below. While quantifying the samples, they were
placed on ice to prevent degradation of the tRNA.

1. Using RNase free water, wash the sampled reader by placing 1µL on both the top
and bottom platforms and dry with a KimWipe.
2. Following the systems instructions, start the program and classify the samples
being tested as “RNA” under settings.
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3. Load 2µL of blank to the lower sensor and initialize the system by clicking
“blank”.
a. Blanks should be the same solution used to dilute tRNA samples in steps
12A, 13A, and 20A during tRNA isolation.
4. Dry the lower sensor and add 1µL of sample.
5. Lower the arm and press “read”.
6. After the sample has been read, record the data with the appropriate RNA
concentration (ng/µl), A260/A280 and A260/A230 ratios.

TRNA REVERSE TRANSCRIPTION WITH cDNA DENATURATION
After the tRNA was quantified, it was reverse transcribed using the protocol
below to create single stranded cDNA. Reverse transcription was performed using the
RETROscript® First Strand Synthesis Kit (Ambion, AM1720) on the Rotor-Gene Q
(Qiagen, 9001863).

1. From the Agilent RNA chip, determine the volume of RNA required to yield 1 µg
of RNA.
2. Add 600ng -1µg RNA to a small PCR tube. FLICK THE TUBE, MAKE SURE
IT’S MELTED.
a. Should have to add no more than 10µL of RNA to the PCR tube to get 1
µg total (however, if you have a low RNA yield you can use as little as
400ng of RNA for reverse transcription).
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3. Add 2µl of oligo dT (1st strand primer for reverse transcriptase – typically mRNA
has poly-AAA tail, so oligo dT binds to it and acts as 1st strand primer) to the
PCR tube containing the RNA.
4. Add nuclease-free water to make a final volume of 12µL in the PCR tube.
5. Mix gently, spin briefly and then heat PCR tube for 3 minutes at 70-85oC in the
thermocycler (see below for more details on how to use the thermocycler).
a. Heating gets rid of the RNA secondary structure that could impede reverse
transcriptase from copying the RNA.
6. Remove PCR tubes from heat and place on ice, spin briefly, and place back on
ice.
7. Add remaining RT components (should end up with 20µL final volume in PCR
tube). KEEP ON ICE.
a. 2µL – 10X RT buffer
b. 4µL – dNTP mix (deoxynucleotide triphosphates- building blocks of the
DNA)
c. 1µL – Rnase inhibitor
d. 1µL – Reverse Transcriptase (makes the cDNA from RNA)
8. Mix gently using pipette at 10µl volume, spin briefly and then incubate at 4244oC for 1 hour in thermocycler.
9. Incubate at 92oC for 10 minutes to inactivate Reverse Transcriptase
10. Add an additional 20µl of DNase-free water to cDNA to yield a final volume of
40ul.
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11. Store resulting cDNA at -20oC or proceed to PCR.

rt- POLYMERASE CHAIN REACTION (rt-PCR)
Once the RNA was reverse transcribed into cDNA, the cDNA was amplified by
real time Polymerase Chain Reaction using the QuantiTect SYBR Green PCR Kit
(Qiagen, 204143) and the protocol below.

1. Total the number of cDNA samples undergoing rt-PCR.
2. Take the total and add one and then multiply it by each of the solutions below:
a. 10µL of master mix
b. 2µL forward primer
c. 2µL reverse primer
d. 4µL RNase free water
3. For each gene of interest, combine the above reaction components together to
create the master mix for that gene.
4. Aliquot 18µL of each respective master mix into 0.5mL PCR tubes.
5. Add 2µL of each respective cDNA template into each tube.
6. Mix gently using pipette at 10µL volume and spin briefly.
7. Place tubes into the RotorGene for 45 PCR cycles of the following:
a. Hold at 95oC for 15 minutes.
b. Cycle
i.

Denature: 94oC for 15 seconds
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ii.

Anneal: 50oC for 20 seconds

iii.

Extension: 72oC for 20 seconds

c. Melt 72-99oC at 1oC per step first hold 30 seconds following hold 5
seconds.

The genes of interest for rt-PCR and their primer sequences, ordered from
Integrated DNA Technologies, can be found below in Table 2.1. Before use, the primers
were diluted from 25µM to a working solution of 5µM by adding 100µL of primer to
400µL of RNase-free water. This was done for the forward and reverse primer for each
gene. The annealing temperature in Step 7.ii. was chosen based on the lowest melting
temperature among all the primers minus two degrees.

Table 2.1: Primer Sequences used for RT-PCR
#

Primer

Species

Forward and Reverse Sequences

Reference

1

COLL-1

Rat

[2]

2

COLL-3

Rat

3

Tenomodulin

Rat

4

Scleraxis

Rat

5

18S

Rat

F: TGGATGGCTGCACGAGT
R: TTGGGATGGAGGGAGTTTA
F: GCCTCCCAGAACATTACATAC
R: CAATGTCATAGGGTGCGATA
F: CCAGACAAGCAAGCGAGGA
R: AACTTCCTATTAGACTCTCC
F: CTGGCCTCCAGCTACATTTC
R: CCGTCTTTCTGTCACGGTCT
F: CGGCGACGACCCATTCGAAC
R: GAATCGAACCCTGATTCCCCGTC
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[2]
[3]
[3]
[4]

rt-PCR DATA AND STATISTICAL ANALYSIS
2-ΔΔCt values were calculated for each sample that was underwent rt-PCR and
normalized to the control group to determine whether there was an up regulation or down
regulation of gene expression. Results were represented as a mean ± the standard
deviation for each gene within a study group. All statistical analyses were performed for
each gene of interest using a two-tailed t-test of unequal variance. Significant differences
were signified by a p < 0.05.

2.3.8. Histological analysis

IMMUNOFLUORESCENCE
Immunofluorescence for prolyl-4-hydroxylase will transmit red, while the DAPI
will fluoresce the nuclei blue.

1. Rinse cells in warm PBS.
2. Fix cells with warm 4% formaldehyde or paraformaldehyde for 30 minutes.
3. Permeabilize with triton for intracellular proteins / transcription factors.
a. For intracellular proteins rinse 4X in PBS after fixing cells and then
permeabilize with 0.2% triton for 5 minutes at room temp. Then rinse
again 3-4X with PBS prior to blocking.
4. Block with blocking solution (BS): 5% bovine serum albumin + 0.05% Triton for
2 hours (can be left overnight) at 4oC.
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5. Remove BS but do not rinse.
6. Add primary antibody diluted according to manufacturers specifications in
blocking solution and place at room temp for 2 hours (or overnight at 4oC).
a. Recover primary antibody following incubation period.
7. Rinse 3-4X with 1x PBS.
8. Add secondary antibody (5µg /mL) diluted in BS for 1 hour at room temperature
in the dark.
9. Rinse 3-4X with 1x PBS.
10. Add DAPI to cover the bottom of the well for 1-5 minutes.

LIVE/DEAD IMAGING
Scaffolds were flipped upside down on a slide to be imaged after staining was
completed.

MATERIALS:
1. Sterile 1X DPBS
2. LIVE/DEAD® Viability/Cytotoxicity Assay Kit (Invitrogen, L-3224)
a. 4mM Calcein AM (component A)
b. 2mM Ethidium homodimer-1 (component B)

METHODS:
1. Calculated the volumes of solutions needed to cover the samples per ratio below:
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a. 1mL DPBS
b. 0.5µL Calcein AM
c. 2µL EthD-1
2. Prepared the final solution:
a. Added EthD-1 to DPBS then vortexed.
b. Added Calcein AM to the solution above and vortexed.
3. Aspirated all culture medium from the well.
4. Rinsed the cells three times with warm DPBS.
5. Added enough of dye solution to the well (approximately 0.5 to 1mL) to cover the
scaffolds.
6. Incubated at 37°C for 20 minutes in a dark place.
7. Allowed the fluorescent lamp to warm for at least 15 minutes.
8. Imaged using fluoresce filters to examine the cells.

2.3.9. Protein analysis

PROTEIN ISOLATION
SOLUTIONS:
1. RIPA Buffer Recipe (for 100mL):
2. 50mM Tris-HCl

0.788 g

3. 150mM NaCl

0.876 g

4. 1mM EDTA

37.2 mg

49

5. 1% Triton X-100

1.0mL

6. 1% Sodium Deoxycholate

1.0 g

7. 0.1% SDS

100 mg

8. pH solution to 7.4
a. Add 10 µl protease inhibitor cocktail (Sigma P-8340) per mL RIPA Buffer
just before use

PROCEDURE:
1.

Rinse each well twice with 3mL of sterile PBS (without Calcium or magnesium).

2. Add 500µL RIPA buffer containing protease inhibitor to each well.
3. Use a rubber cell scraper (blue handle with white rubber windshield wiper looking
thing on the end) and vigorously scrape the entire surface of the well.
4. Transfer the solution in each well to 2mL centrifuge tubes using a 1mL pipette.
Sonicate the material for 5 minutes, followed by 15 seconds of homogenization
with metal tip in sterile 12 x 75 mm glass tube.
a. Clean the tip before and after use in one change of 100% ethanol followed
by one change of distilled water.
5. Place on ice and let the solution cool for 20 minutes.
6. Spin down the samples in the small centrifuge at 14,000 g for 15 minutes.
7. Transfer supernatant (liquid on top) into two new 2 mL microfuge tubes and place
in the -20C freezer until BCA performed.
8. Solid pellet at the bottom of the tubes can be discarded.
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BCA PROTEIN ASSAY
Once the protein was isolated, the concentration was determined using a BCA
Protein Assay Kit (Thermo Scientific Pierce, 23225). Diluted Albumin standards (BSA)
was mixed according to the Pierce dilution scheme for standard test tube protocol and
microplate procedure (working range = 20 – 20,000µg/mL) [5]. BCA working reagent
was created and the microplate was prepared according to the Pierce instructions as well.
After the 30-minute incubation in step 3, wells were allowed to cool for 5 minutes prior
to wavelength reading. After BCA values were obtained, the value of the 562 nm
measurement for the blank was subtracted from the 562nm measurement for the
standards and unknowns. Using these values, a standard curve was plotted using the
corrected standard 562nm measurements against the known concentration for each
standard in µg/mL. This curve was used to determine the protein concentration of the
unknowns.

MICROCON CENTRIFUGAL FILTER DEVICE TO CONCENTRATE PROTEIN
For samples that were not concentrated enough to obtain the desired concentration
in 50µL of liquid, which is the maximum amount of liquid the well plate can hold, they
were concentrated using the Bioseparations Centrifugal Filter Device Microcon YM-3
(Millipore, 42404). First, the tubes were labeled and the samples were loaded into the
filter reservoir (maximum 0.5 mL). After securing the tops, the height of the sample in
the filter was marked. Samples were then spun at 14,000xg for 45 minutes and the height
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of samples was checked. Ideally, a 5-10 fold increase in protein was wanted. Then, the
sample reservoir was removed from the vial and inverted into a new clean vial. The vial
was spun in the Microfuge for 3 minutes at 1,000xg to transfer concentrate to the vial.
Three sample reservoirs for the sample study group were combined to obtain an n=2.
Once completed, the samples were separated from the reservoir and stores at -20°C until
BCA quantification was performed.

SDS PAGE AND WESTERN BLOT
Western blotting was performed using the protocol below to aid in determining
protein concentrations among the study groups. For each western blot, 7µg of protein was
desired in each lane during electrophoresis.

MATERIALS:
1. BM Chemiluminescence Western Blotting Kit (Mouse/Rabbit) (Roche Applied
Science, 11520789001)
2. Ready gels 4-15% Tris-Acl 50uL, 10 wells (Biorad, 161-115B)

SDS PAGE/ELECTROPHORESIS:
1. Sample preparation:
a. Add appropriate amount of protein (to get 7µg) and sample buffer (to get a
total of 40µL) into a 50µL tube (want a 1:1 ratio of protein to sample
buffer so base concentration of sample buffer on how much is needed).
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b. Add 4µL B-mercapthoethanol to each sample.
c. Boil each sample for 5 minutes to break disulfide bonds.
2. Make 2X Tris/glycine/SDS migration buffer (~500 mL per electrophoresis unit).
a. 50 mL of 10X Tris/glycine/SDS buffer + 450 mL dH2O
3. Insert gels with the comb (ridges) on the inside.
4. Close clip simultaneously.
5. Fill middle between gels with migration buffer until its half way between the top
of the comb and the top of the plastic holding the gel.
6. Check for leaks. If there are none, add the remaining migration buffer to the edges
of the gels.
7. Remove combs from the gels (use fingernails in the ridges)
8. Load a max of 40µL of unknown samples in each lane and 15µL of MW standard.
9. Run gel at 90V for 100 minutes while on ice.

SOLUTIONS:
1. TB–Transfer Buffer : 6.06g Tris, 28.8g Gly, 200 mL MetOH – fill to 2L with
dH2O
2. Tris 50mM (12.1g), NaCl 150mM (17.52g), - 2L with dH2O, pH 7.5
3. Tris – Tween : 1 mL Tween20 in 1 liter Tris buffer
4. NFDM (non-fat dried milk) 2% in Tris buffer (500 mL) – 10g NFDM +
500mLTris
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WESTERN BLOT:
A. Preparing PVDF membranes:(1 per gel) (start preparing 30-45 minutes prior to the
end of the electrophoresis run)
1. Cut out PVDF (polyvinylidine fluoride) membrane using sizing jig (in bottom of
membrane box).
a. Do not touch membrane; only use the tweezers at the corner once it is
removed from between the two blue sheets. Cut bottom left corner of
membrane for orientation.
2. Place membrane in 100% methanol for 20 seconds, then place in H2O for 2
minutes (make sure the membrane is remains submerged here because it has a
tendency to float), finally place membranes in transfer buffer for at least 5
minutes.
3. When electrophoresis gels are done running, remove from electrophoresis module
and pry off the glass plate covering the gel. Remove the top gel / fringes. Place
each gel in its own container containing transfer buffer. Allow the gels to
equilibrate to room temperature for 15 minutes.
4. During equilibration time, wash the electrode holder box/bath to remove SDS,
this needs to be clean so that we can use this module with the transfer cell.
5. After equilibration of gels in transfer buffer, we are ready to make the gel
sandwich for transferring the protein to the PVDF membrane. Be sure to pre-soak
components including fiber and filter pads in transfer buffer in two glass pyrex
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pans. Will build gel sandwiches in one pyrex pan while the other is used for presoaking the sandwich components.
6. Stack gel sandwich as follows:
Gel sandwich: avoid air bubbles!
Top:
--------------- clear side of the cassette (with handle)
--------------- pre-wetted fiber pad
--------------- pre- wetted filter paper
--------------- PVDF membrane
--------------- gel
--------------- pre-wetted filter paper
--------------- pre-wetted fiber pad
--------------- black side of the cassette
Bottom
7. Once stacking is complete, roll a glass pipette over the top fiber pad to remove
any air bubbles prior to closing the cassette.
8. Place black side of cassette facing the black side of the transfer cell (red and
black).
9. Place transfer cell into clean electrophoresis module that contains a small stir bar
in the center and fill with transfer buffer.
a. Transfer cell: Electrode module, ice pack, 1-inch stir bar, TB → all in a
ice bucket full ice
10. Run electrophoresis module for 75 minutes at 100 V, make sure to surround
module with ice and water.

B. Processing of PVDF membranes – Equilibrate all solutions at RT
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11. Before blocking carefully remove the membrane from the sandwich. Mark the
side facing the gel with a “J” or something to distinguish it and cut the bottom
corner below the last MW marker.
12. Block blots in 100 mL 2% NFDM (50mL/blot), at least 1 hour (shaking) –did 1.5
hours
13. Incubate the membrane over night at 4 o C without shaking in 1o Ab in 0.5%
NFDM. Allow equilibrating to RT before washing.
14. Wash: 3X 15 min. in 100 mL Tris-Tween while shaking
15. Change containers and wash 2X 12 min in 50 mL 0.5% NFDM in Tris while
shaking.
16. Incubate the membrane for 45-90 minutes with shaking in 2 o Ab (3.6µL in 60mL
1% NFDM for anti mouse/rabbit kit) (30mL/blot)
17. Wash : 4X 15 min. in 100 mL Tris – Tween.
18. Transfer to a new container with Tris buffer.
19. During the wash:
a. Prepare detection solution: 250µL B (starting solution) + 25 mL A
(substrate solution). Wrap in tinfoil until used in order to keep dark.
20. Image

WESTERN BLOT ANALYSIS
To determine the relative density units (RDU) for each membrane, ImageJ
software was used. Each lane of the membrane containing a sample was selected using a
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uniformly sized box. The light density within the box was then measured and graphed to
determine the peak density.

2.3.10. Decellularized porcine pericardium preparation

Porcine pericardium was used as a scaffold for cell seeding medium as described
later. Prior to use, the pericardium was decellularized by lab member Mike Jaeggli.

1. Punch out non-sterile decellularized pericardium using a 12 mm biopsy punch.
2. Sterilize for 2 hours in 0.1% peracetic acid made in PBS, pH to 7.4.
3. Place pericardial punches in peracetic acid in P cup and put on orbital shaker for 2
hours and 35 minutes.
4. Rinse thoroughly in 4 changes of sterile PBS, rinse for 15 minutes each change.
5. Following rinsing, incubate sterile pericardial punches in sterile solution of 50%
FBS, 1% Ab/Am, and 50% DMEM (1g/L glucose) for two hours, prior to cell
seeding.

2.3.11. Confirmation of Adipose Derived Stem Cell multilineage differentiation
capability

To validate the multipotency, or stemness, of the isolated Lewis rat Adipose
Derived stem cells at passage 4, the cells were cultured in chondrogenic, adipogenic, and
osteogenic medias, as detailed in Table 2.2, to induce differentiation. The listed medias
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have shown to induce Chondrogenesis, Adipogenesis, and Osteogenesis, respectively, in
Mesenchymal Stem Cells [6, 7]. For each group, cells were cultured in a total of six wells
containing 2mL of their respective differentiation media at the appropriate density listed
below. Media was exchanged in the wells every three days. Analysis was performed after
the differentiation period using histological stains, as described in Table 2.3, to confirm
multilineage differentiation. Each stain was passed through a 0.4µm filter beforehand to
remove debris, however Whatman papers would have allowed for a darker stain.
Table 2.2: Medium Supplementation for Induced Lineage-Specific Differentiation of
LRAD Stem Cells
Differentiation
Medium

Basal Medium

Serum

Supplementation

Control
Chondrogenic
(CM)

DMEM (1g/L Glucose)
DMEM (1g/L Glucose)

10% FBS
1% FBS

Adipogenic
(AM)

DMEM (1g/L Glucose)

10% FBS

Osteogenic
(OM)

DMEM (1g/L Glucose)

10% FBS

1% antibiotic/antimycotic
6.25µg/mL insulin, 10ng/mL
TGF-β1, 50nM ascorbate-2phosphate, 1%
antibiotic/antimycotic
0.5mM isobutyl-methylxanthine
(IBMX), 200µM
indomethacin, 10µM insulin,
1µM dexamethasone, 1%
antibiotic/antimycotic
1.1µM dexamethasone, 10mM
β-glycerophosphate, 50µM
ascorbate-2-phosphate, 1%
antibiotic/antimycotic

CHONDROGENESIS
The LRAD stem cells were placed in a micromass and cultured to induce
chondrogenic differentiation [6,8]. Each cell micromass was suspended in 10µL of the
control media, as listed in Table 2.2, at a density of 8 x 106 cells/mL in the center of each
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well. The cells were allowed to attach for 2 hours at 37°C, followed by the gentle
addition of chondrogenic media (CM) as to not disturb the cell pellet.
Chondrogenesis confirmation analysis was performed after cells were cultured in
CM for a total of 27 days using Alcian Blue (Poly Scientific, K066) histological stain at
an acidic pH of 0.81. Prior to staining, the cells were rinsed three times with sterile
phosphate buffered saline (PBS) to remove the media, then fixed in 4%
paraformaldehyde for 30 minutes at room temperature, and subsequently rinsed three
times with distilled water (dH2O) to remove any residual chemicals. Due to the fact that
previous studies have shown staining capabilities of sulfated glycosaminoglycan’s, which
are present in cartilaginous matrices, by 1% (wt/vol) Alcian Blue in 0.1 N HCl (pH levels
of 1 and below), the cells were then submerged in 3 mL of Alcian Blue 1% in 3% Acetic
Acid pH 0.81 for 30 minutes at room temperature [6]. The cells were then rinsed with
dH2O to remove excess stain and the cells remained submerged in it until imaging.

ADIPOGENESIS
A total of 1x106 Lewis rat Adipose Derived Stem Cells were seeded into each of
the six wells of a six well plate and adipogenic differentiation of the stem cells was
induced by culturing with AM, as described in Table 2.2, for a total of 28 days. The cells
were then rinsed three times with PBS to remove residual media and fixed for 60 minutes
with 4% paraformaldehyde at room temperature. Next, the cells were rinsed twice with
distilled water, followed by one quick rinse of 60% isopropanol and then a five-minute
rinse with 60% isopropanol. To examine for intracellular lipid-filled vacuoles, as
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described in Table 2.3, the cells were then stained at room temperature for 60 minutes in
5% Oil Red-O working solution made in 99% isopropanol that was stirred overnight and
filtered through a 0.4µm media filter [6]. The stain was then removed with one rinse of
60% isopropanol and three subsequent rinses of distilled water. The cells were
counterstained for one minute with Hematoxylin and rinsed until the distilled water was
clear. The cells were immediately imaged.

OSTEOGENESIS
Lewis rat Adipose Derived Stem Cells were cultured with Osteogenic media, as
detailed in Table 2.2, to induce osteogenic differentiation. Each of the six wells were
seeded with 100,000 cells and allowed to differentiate for a total of 27 days. Cells were
then rinsed three times with 3mL PBS in each well to remove the excess media and fixed
for 30 minutes at room temperature using 4% paraformaldehyde. The cells were then
rinsed with dH2O three times to remove any residual chemicals and stained with 3mL 1%
Alizarin Red S working solution (PHG) (pH 6.00), as described in Table 2.3, for two
minutes at room temperature to examine extracellular matrix calcium deposition. After,
the cells were rinsed four times with distilled water to remove excess stain and remained
submerged until imaging [6].
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Table 2.3: Histological Staining to Confirm Induced Lineage-Specific Differentiation of
LRAD Stem Cells
Lineage

Histological
Stain

Working Solution

Chondrogenic

Alcian Blue
stain

Stock

Adipogenic

Oil Red-O
stain

1. 0.5gms of Oil Red-O powder
added into 100mL of isopropanol
(aq) and mixed overnight
2. Add 6mL of stock from above
into 4mL distilled water
Stock

Osteogenic

Hematoxylin
counterstain
Alizarin Red

10mL of Ammonium Hydroxide
0.1% (aq) added to 100mL of
Alizarin Red S 1% (aq)

Lineage-Specific
Determinant
Sulfated
glycosaminoglycan
deposition
Intracellular lipid
accumulation

Cell nuclei
Extracellular matrix
calcium deposition

2.3.12. Differentiation studies

In order to differentiate the Lewis rat Adipose Derived Stem Cells into tenocytes,
the cells were seeded into six well plates. Depending on the study group, the cells were
either exposed to medium containing 50ng/mL BMP-12, 10ng/mL Recombinant Human
TGF-β1 (PeproTech, 100-21), a combination of the two, or DMEM control media. Each
medium contained 1% Ab/Am, along with varying levels of FBS depending on the study,
which can be seen below in Table 2.4. Subsequently, the cells were placed in either a
static condition or a dynamic condition where the cells were undergoing biaxial tension
(FlexCell Int.) to determine whether a particular condition enhanced differentiation.

61

Table 2.4: Lewis Rat Adipose Derived Stem Cell Medium Supplementation for
Differentiation Studies
Study
Prestudy

Study 1

Study 2

Study 3

Group

Basal Medium*

Expansion MesenPro Basal
Media

Serum

Supplementation
1% antibiotic/antimycotic
200mM L-glutamine

Control

DMEM/F12

2% MesenPro
Rs Growth
Supplement
2% FBS

BMP-12

DMEM/F12

2% FBS

Control

DMEM/F12

2% FBS

BMP-12

DMEM/F12

2% FBS

Control
BMP-12

DMEM
DMEM

10% FBS
10% FBS

TGF-β1

DMEM

10% FBS

BMP-12 +
TGF-β1

DMEM

10% FBS

Control
BMP-12

DMEM
DMEM

10% FBS
10% FBS

TGF-β1

DMEM

10% FBS

Control
BMP-12

DMEM
DMEM

10% FBS
10% FBS

Study 4

Study 5

1% antibiotic/antimycotic
1X ITS**
1% antibiotic/antimycotic
1X ITS
50ng/mL BMP-12
1% antibiotic/antimycotic
1X ITS
1% antibiotic/antimycotic
1X ITS
50ng/mL BMP-12
1% antibiotic/antimycotic
1% antibiotic/antimycotic
50ng/mL BMP-12
1% antibiotic/antimycotic
10ng/mL TGF-β1
1% antibiotic/antimycotic
50ng/mL BMP-12
10ng/mL TGF-β1
1% antibiotic/antimycotic
1% antibiotic/antimycotic
50ng/mL BMP-12
1% antibiotic/antimycotic
10ng/mL TGF-β1
1% antibiotic/antimycotic
1% antibiotic/antimycotic
50ng/mL BMP-12

*All basal medium contained 1g/L Glucose
**ITS composed of 500ng/mL insulin, 500ng/mL transferrin, and 500ng/mL selenium
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STUDY 1: DETERMINING THE IDEAL MECHANICAL DIFFERENTIATION
CONDITION: DYNAMIC LOADING VS STATIC
The first study focused on gene expression and histology of differentiated Lewis
rat Adipose Derived Stem Cells at passage 3. Cells were expanded in MesenPro
Complete medium and either cultured on BioFlex–Collagen Type I coated 6-well plates
(FlexCell International Corp., BF-3001C-Each) or on monolayer for 8 days. All cells
were seeded in their respective 6-well surface type and placed into the 37°C incubator for
24 hours beforehand to ensure cell attachment prior to a seven day static or dynamic
period. A seeding density of 500,000 cells per well was used in wells being analyzed for
gene expression (n=3 wells), whereas a seeding density of 100,000 cells per well was
used in wells being evaluated for histological analysis (n=3 wells). There were a total of
three groups for this study: dynamic surface with medium containing BMP-12 (n=6
wells), dynamic surface with control medium not containing BMP-12 (n=6 wells), and
static surface with medium containing BMP-12 (n=6 wells). The dynamic regimen can be
found below in Table 2.5.

Table 2.5: Regimen for Dynamic Testing
Day

Min Tension %

Max Tension %

Duration (hours)

1
2
3
4
5
6
7

0
0
0
0
0
0
0

2.5
5
7.5
7.5
7.5
7.5
7.5

6
6
6
6
6
6
6
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As shown in Table 2.4, each medium was made with DMEM/F12 (1g/L glucose),
and additionally, contained only 2% FBS, and 1x ITS (500ng/mL Insulin, 500ng/mL
Transferrin, 500mg/mL Selenium). At the end of the 8th day, immunofluorescence (IF)
was performed for histological analysis to determine the presence and abundance of
Prolyl-4-hydroxylase within the static group according to the protocol above. Mouse antirat monoclonal anti-prolyl 4-hydroxylase β primary antibody (Millipore, MAB2073MI)
was used for IF at a dilution of 1:500 in blocking solution. Goat anti-Mouse IgG
(Invitrogen, 110-33) was used as the secondary antibody. Two wells from each study
group were allotted for each protein of interest, one well as a positive control with
primary and secondary antibody steps and one well as a negative control with PBS and
secondary antibody steps. In order to image the cells stained on the Collagen type I
coated plates, the bottom of the well was cut out and placed upside-down on the slide.
Cells cultured for molecular analysis were trypsinized using 0.5mL media for six
minutes and then neutralized with 3mL media. After cells were dislodged, they were spun
down and re-suspended in RNAlater in RNase free tubes and tRNA was isolated using
the protocol above.
Gene expression was analyzed by quantifying the RNA using the Agilent
Bioanalyzer Chip, reverse transcribing the tRNA and preforming rt-PCR using the above
protocols. The genes of interest included Collagen type I, Collagen type III, Scleraxis,
and Tenomodulin with 18S as the housekeeping gene (as listed in Table 2.1). Isolated
tenocytes were used as a positive control and undifferentiated stem cells cultured in
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control media for seven days were used as a negative control for gene analysis. PCR 2ΔΔCt

values were normalized to the negative control to determine relative expression.

STUDY 2: DETERMINING THE IDEAL DIFFERENTIATION PERIOD: 7 VS 14
DAYS
The second study focused on gene expression (n=18 wells) and histological
expression (n=6 wells) of cells cultured in BMP-12 in static conditions for both seven
and 14 days on monolayer. A seeding density of 100,000 cells per well in a six-well plate
was used. Each group was cultured in DMEM/F12 (1g/L glucose) with 2% FBS, 1%
Ab/Am, 1X ITS, and 50ng/mL BMP-12, as stated in Table 2.4, and the media was
changed every three days during the study period. Live/Dead histological staining was
performed on the scaffolds at the end of seven and 14 days to determine the viability of
the cells according to the protocol above.
To isolate tRNA for gene expression analysis via rt-PRC, the cells were removed
from the 6-well plate using trypsin. Trypsin was allowed to sit for 5 minutes at 37°C and
the neutralized with 10x the volume of control media. Three wells were pooled and three
scaffolds were pooled within individual study groups for both time periods (n=6
samples). After isolation, the tRNA was quantified using the Agilent Bioanalyzer Chip,
the tRNA was reverse transcribed, and rt-PCR was preformed on the cDNA for Collagen
type I, Collagen type III, Scleraxis, and Tenomodulin with 18S as the housekeeping gene
(as listed in Table 2.1). All samples were normalized to undifferentiated Lewis rat
Adipose Derived Stem Cells cultured on monolayer for statistical analysis. All gene work
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was performed according to the protocols above. Media samples were also collected from
the wells every three days when the media was changed and stored at -80°C.

STUDY 3: DETERMINING THE IDEAL DIFFERENTIATION SUPPLEMENTATION
USING GENE ANALYSIS: BMP-12, TGF- Β1, OR A COMBINATION
The third study focused on the gene expression of cells cultured in static
conditions for seven days and 14 days on monolayer at passage 4. Cells were seeded in
six well plates at a density of 100,000 cells per well. Control cells were cultured at each
time point (n=3, 3, 6 respectively) in control medium with DMEM (1g/L glucose) with
10% FBS, and 1% Ab/Am, containing no additional supplement. Experimental groups
were cultured in the same media with 50ng/mL BMP-12 (n= 12 wells), 10ng/mL TGF-β1
(n=12 wells), or a combination of the two, added as described in Table 2.4. For each
media at each time point there was an n=6 wells.
For tRNA isolation at each time point, trypsin was not used to detach the cells
from the well plate surface. Instead, 350µL RLT buffer was placed into the well and the
cells were removed with a cell scraper. After isolation, tRNA was quantified using the
NanoDrop 2000. Gene expression was evaluated for each study group and time point
using the protocols above. rt-PCR was preformed on the cDNA for Collagen type I,
Collagen type III, Scleraxis, and Tenomodulin with 18S as the housekeeping gene (as
listed in Table 2.1). Isolated tenocytes were used as a positive control and
undifferentiated stem cells cultured in control media for either seven days or 14 days
were used as a negative control for gene analysis. PCR 2-ΔΔCt values were normalized to
the negative control at the respective culture period to determine relative expression.
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STUDY 4: DETERMINING THE IDEAL DIFFERENTIATION SUPPLEMENTATION
USING PROTEIN ANALYSIS: BMP-12, TGF- Β1, OR A COMBINATION
The fourth study focused on the protein expression of Lewis rat Adipose Derived
Stem Cells at passage 5. Cells were cultured in static conditions for seven days (n =18
wells) and 14 days (n= 18 wells) on monolayer in six well plates. A seeding density of
100,000 cells per well was used. Control groups were cultured in DMEM (1g/L glucose)
with 10% FBS, and 1% Ab/Am. The same solutions were used for the two experimental
groups, in addition to either 50ng/mL BMP-12 or 10ng/mL TGF-β1. Proteins were
isolated from the wells using RIPA buffer and protein expression for each study group
was analyzed using the respective protocols above. The proteins of interest included
Collagen type I, Collagen type III, Scleraxis, and Tenomodulin. The antibodies and the
dilutions in 0.5% non-fat dried milk that were used are as follows: Anti-Collagen I
antibody diluted 1:5000 (Abcam, ab34710), Anti-Collagen III antibody diluted 1:5000
(Abcam, ab7778), Anti-SCXA antibody diluted 1:10,000, 1:1000, and 1:200, (Abcam,
ab58655), and Tenomodulin diluted 1:200 (Santa Cruz Biotech, Inc., sc-98875).
Membranes were analyzed using the protocol above. The following densities were used
to find the protein band: 22kDa for Scleraxis, 37.1kDa for Tenomodulin, 122kDa for type
I collagen, and 138kDa for type III collagen. Media samples were also collected every
three days when the media was changed and stored at -80°C.
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STUDY 5: DETERMINING THE IDEAL DIFFERENTIATION SURFACE:
MONOLAYER VS. DECELLULARIZED PORCINE PERICARDIUM
The fifth study focused on the gene expression of Lewis rat Adipose Derived stem
cells seeded on 1) decellularized porcine pericardium scaffolds supplied by Mike Jaeggli
and 2) on monolayer. The scaffolds were cut into 18mm circles using a sterile punch, cut
into half-moons, and sterilized using the protocol above. Cells were either cultured in
BMP-12 differentiation media (n-6 wells) or control media (n=6 wells) as described in
Table 2.4. A seeding density of 1,000,000 cells per scaffold was used.
tRNA was isolated from the scaffolds using the protocol above. After isolation,
tRNA quantification was determined using the NanoDrop 2000. Gene expression was
evaluated for each study group using the reverse transcription and rt-PCR protocols
above. rt-PCR was preformed on the cDNA for Collagen type I, Collagen type III,
Tenomodulin, and Scleraxis (rat), with 18-S as the housekeeping gene (listed in Table
2.1). Isolated tenocytes were used as a positive control and undifferentiated stem cells
cultured in control media for seven days were used as a negative control for gene
analysis. PCR 2-ΔΔCt values were normalized to the negative control to determine relative
expression where possible. There were not enough tenocyte and BMP-12 samples to
determine standard deviations and therefore statistical differences may not be indicated.

2.4.

Results

2.4.1. Confirmation of Adipose Derived Stem Cell multilineage differentiation
capability
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Once the Adipose Derived Stem Cells were cultured in their appropriate
mediums, they were stained to ensure differentiation had occurred. Lewis rat Adipose
Derived stem cells cultured in CM under micromass conditions were stained for GAGs
using Alcian Blue (Table 2.3) and as you can see in Figure 2.1, there is GAG content
present.

Figure 2.1: Histological staining of isolated Lewis rat Adipose Derived Stem Cells that
have undergone Chondrogenesis. The cells are stained with Alcian Blue for sulfated
glycosaminoglycan deposition to ensure differentiation.
Cells cultured with AM to induce Adipogenesis were stained with Oil Red-O to
observe intracellular lipid accumulation. As you can see below in Figure 2.2, the cells did
exhibit lipid accumulation, although not all the cells stained positively.
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Figure 2.2: Histological staining of isolated Lewis rat Adipose Derived Stem Cells that
have undergone Adipogenesis. The cells are stained with Oil Red-O for intracellular lipid
accumulation to ensure differentiation.
Lastly, LRAD stem cells cultured in OM to induce Osteogenesis stained
positively, as shown in Figure 2.3, for extracellular calcium deposition.

Figure 2.3: Histological staining of isolated Lewis rat Adipose Derived Stem Cells that
have undergone Osteogenesis. The cells are stained with Alizarin Red for extracellular
calcium deposition to ensure differentiation.
As depicted in the Figures above, the ADSCs isolated from the Lewis rats are
capable of differentiating down multiple lineages, signifying they are multipotent and
capable of differentiating into tenocytes.
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2.4.2. Study 1: Determining the ideal mechanical differentiation condition:
dynamic loading vs. static

Cells cultured in BMP-12 differentiation media on monolayer for seven days
fluoresced positively for prolyl-4-hydroxylase, confirming the fibroblast-like nature of
the cells characteristic of tenocytes. Negative controls not incubated in secondary
antibody did not fluoresce positively, as shown below in Figure 2.4.
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PROLYL/4/HYDROXYLASE(
POSITIVE(

NEGATIVE(CONTROL(

Figure 2.4: Prolyl-4-hydroxylase immunofluorescence staining on cells cultured on
monolayer for seven days in BMP-12 differentiation media.
PCR results have shown that gene expression is higher in the static group cultured
in BMP-12 for seven days than in the dynamic group for Collagen I, 2.37 and 0.59,
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respectively. Collagen type I gene expression is also significantly higher for cells
cultured on static surfaces for seven days, 2.37, than cultured tenocytes, 0.28. PCR has
also shown that cells cultured statically, 5.12, and dynamically, 3.56, both have an
increase in type III collagen than cultured tenocytes on monolayer, 0.01. These results
can be seen below in Figure 2.5.
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Figure 2.5: Relative fold increase or decrease in gene expression of A) Scleraxis, B)
Tenomodulin, C) Collagen type I, and D) Collagen type III among cells cultured
statically (red) or dynamically (teal), and cultured tenocytes (grey). A connecting
horizontal line at the top of the graph represents statistical differences between groups.
Standard error bars are present. All values were normalized to undifferentiated Adipose
Derived Stem Cells (n=3).
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2.4.3. Study 2: Determining the ideal differentiation period: seven vs. 14 days

Cells cultured in BMP-12 differentiation media on monolayer are capable of
staying alive for a minimum of seven days, as shown in Figure 2.6 below. Live cells
fluoresce green and dead cells fluoresce red.

Figure 2.6: Live/Dead imaging of ADSCs cultured on monolayer in BMP-12
differentiation media for seven days.
PCR results have shown that gene expression is higher in the group cultured in
BMP-12 for seven days than in the group cultured for 14 days for type I collagen, 1.29
and 0.54, respectively. These cells cultured for seven days and 14 days also show an
increased expression of type I collagen compared to cultured tenocytes, 0.06. However,
cells cultures for seven days in BMP-12 expressed Scleraxis significantly less than
cultured tenocytes, 0.45 and 2.11, respectively. These results can be seen below in Figure
2.7.
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Figure 2.7: Relative fold increase or decrease in gene expression of A) Scleraxis, B)
Tenomodulin, C) Collagen type I, and D) Collagen type III among cells cultured
statically for seven (orange) or 14 days (purple), or compared to cultured tenocytes
(grey). A connecting horizontal line at the top of the graph represents statistical
differences between groups. Standard error bars are present. All values were normalized
to undifferentiated Adipose Derived Stem Cells (n=3).

2.4.4. Study 3: Determining the ideal differentiation supplementation using gene
analysis: BMP-12, TGF- β1, or a combination

PCR has shown that at day 7, BMP-12 evokes a significantly higher expression of
Scleraxis, 57.81, compared to TGF-β1, 12.54, the combination of BMP-12 and TGF-β1,
0.85, and tenocytes, 0.01. After 14 days of differentiation, BMP-12 evoked a statistically
higher expression of Scleraxis, 1.29, than the combination differentiation group, 0.44, or
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cultured tenocytes, 0.09. TGF-	
  β1 also caused the cells to significantly increase the
expression of Scleraxis, 1.29, compared to tenocytes, as shown in Figure 2.8. When
comparing expression levels for each treatment from day seven to day 14, we see that
Scleraxis expression is higher in the group differentiated in BMP-12 for seven days,
57.81, versus 14 days, 1.29, and ADSCs cultured in the combination of BMP-12 and
TGF-β1 for seven days, 6.69, versus 14 days, 0.44.
Tenomodulin expression is significantly decreased in all groups at day 14
compared to tenocytes, 120.02. There are no statistical differences in Tenomodulin
expression between the experimental groups cultured for seven days, nor are there any
statistical differences in Tenomodulin expression levels from day 7 to day 14 within any
of the experimental groups, as shown in Figure 2.9.
At seven days, BMP-12 differentiation also evokes a significantly higher
expression of Collagen I, 3.66, compared to TGF-β1 differentiation, 2.04, to combination
differentiation using BMP-12 and TGF-β1, 0.85, and to tenocytes, 0.01. Cells
differentiated for seven days in TGF-β1 also significantly increased expression of
Collagen type I than tenocytes. At 14 days, TGF-β1 differentiation also elicited a higher
expression of type I collagen than BMP-12 differentiation, 0.44, combination
differentiation using BMP-12 and TGF-β1, 0.53, and cultured tenocytes, 0.01. In
addition, cells cultured in BMP-12 for seven days expressed Collagen type I significantly
higher than cells cultured in BMP-12 for 14 days, as shown in Figure 2.10. Lastly, there
were no significant differences in the expression of type III collagen between any of the
groups or between the two time points for each gene of interest, as seen in Figure 2.11.
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Figure 2.8: Relative fold increase or decrease in gene expression of Scleraxis among
Lewis rat Adipose Derived Stem Cells cultured in BMP-12 or TGF-β1, a combination of
BMP-12 and TGF-β1, or tenocytes for seven (orange) and 14 days (purple). Statistical
analysis was performed A) across each group within the same time point or B) within
each group across the two time points. A connecting horizontal line at the top of the
graph represents statistical differences between groups. Standard error bars are present.
All values were normalized to undifferentiated Adipose Derived Stem Cells (n=3).
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Figure 2.9: Relative fold increase or decrease in gene expression of Tenomodulin among
Lewis rat Adipose Derived Stem Cells cultured in BMP-12 or TGF-β1, a combination of
BMP-12 and TGF-β1, or tenocytes for seven (orange) and 14 days (purple). Statistical
analysis was performed A) across each group within the same time point or B) within
each group across the two time points. A connecting horizontal line at the top of the
graph represents statistical differences between groups. Standard error bars are present.
All values were normalized to undifferentiated Adipose Derived Stem Cells (n=3).
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Figure 2.10: Relative fold increase or decrease in gene expression of Collagen type I
among Lewis rat Adipose Derived Stem Cells cultured in BMP-12 or TGF-β1, a
combination of BMP-12 and TGF-β1, or tenocytes for seven (orange) and 14 days
(purple). Statistical analysis was performed A) across each group within the same time
point or B) within each group across the two time points. A connecting horizontal line at
the top of the graph represents statistical differences between groups. Standard error
bars are present. All values were normalized to undifferentiated Adipose Derived Stem
Cells (n=3).
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Figure 2.11: Relative fold increase or decrease in gene expression of Collagen type III
among Lewis rat Adipose Derived Stem Cells cultured in BMP-12 or TGF-β1, a
combination of BMP-12 and TGF-β1, or tenocytes for seven (orange) and 14 days
(purple). Statistical analysis was performed A) across each group within the same time
point or B) within each group across the two time points. A connecting horizontal line at
the top of the graph represents statistical differences between groups. Standard error
bars are present. All values were normalized to undifferentiated Adipose Derived Stem
Cells (n=3).

2.4.5. Study 4: Determining the ideal differentiation supplementation using protein
analysis: BMP-12, TGF- β1, or a combination

Studies revealed that there was no Scleraxis protein expression or type III
collagen protein expression at either time point. However, cells cultured in BMP-12 for 7
days exhibited the highest expression of Tenomodulin, followed by BMP-12 culture cells
at day 14. Cells cultured in TGF-β1 for seven days expressed more Tenomodulin protein
than at 14 days, however cells cultured in the combination media expressed higher
amounts of Tenomodulin at day 14 than at day seven. Collagen type I protein expression
was higher at day seven for cells cultured in BMP-12 differentiation media and TGF-β1
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differentiation media, however cells cultured in a combination expressed more Collagen
type I at day 14 than at day seven. Such results can be seen below in Figure 2.12.
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Figure 2.12: A) Scleraxis. B) Tenomodulin, C) Collagen type I, and D) Collagen type III
protein expression (Relative Density Unit) of ADSCs differentiated in either BMP-12
media, TGF-β1 media, or media containing BMP-12 and TGF-β1. The cells were
cultured for a total of seven days (orange) and 14 days (purple).
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2.4.6. Study 5: Determining the ideal differentiation surface: monolayer vs.
decellularized porcine pericardium

Scleraxis expression and type III collagen appears to be higher for cells cultured
in BMP-12 differentiation media on scaffolds compared to undifferentiated ADSCs
cultured on scaffolds. However, cultured tenocytes have the highest expression of both
Scleraxis and Tenomodulin. These results can be seen below in Figure 2.13.
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Figure 2.13: Relative fold increase or decrease in gene expression of A) Scleraxis, B)
Tenomodulin, C) Collagen type I, and D) Collagen type III for BMP-12 differentiated
cells cultured on scaffolds (teal) and undifferentiated cells cultured on scaffolds (pink)
for seven days, or compared to cultured tenocytes (grey). All values were normalized to
undifferentiated Adipose Derived Stem Cells (n=3).
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2.5.

Discussion

Following along with the findings of Zuk et al., Lewis rat inguinal cells were
proven to be multipotent adipose derived Mesenchymal stem cells capable of
differentiation into tenocytes, as shown by the yellow box in Figure 2.14 [6]. However,
the differentiation media and conditions had to first be optimized. Scott et al. showed that
differentiation of cells under dynamic conditions for 2 hours a day increased expression
levels of scleraxis and collagen I, and this was exacerbated by increased strain
percentages up to 7.5%. Past 7.5% strain, there were no statistical differences in the
expression of scleraxis or collagen I [9]. However, results from Study 1 follow the results
of Subramony et al. more succinctly. Their studies showed that at 7 days, there were no
statistical differences in scleraxis, tenomodulin, or collagen I gene expression levels
when comparing cells subjected to tensile strain. However, collagen III gene expression
levels were up-regulated in the group subjected to loading [10]. However, this upregulation alone without the up-regulation of collagen I may not be a good thing because
with injury occurs within a tendon, there tends to be a higher collagen III presence when
the tendon is healed compared to healthy tendon, reducing the mechanical properties of
the tendon. Therefore, the cells undergoing loading and expressing high levels of
collagen III may be a result of the cells being stimulated to think they being damaged,
and therefore laying down this collagen III.
In comparison, it was found in Study 1 that Collagen I expression levels were
significantly up-regulated in the static differentiation group compared to the dynamic
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differentiation group, and scleraxis appeared to follow the same trend. This could
potentially be due to the fact that cells were undergoing biaxial loading instead of
uniaxial loading, which is less similar to physiological conditions within a tendon and
therefore doesn’t promote differentiation into a tenocyte. It was also noted that none of
the ADSCs exhibited significant changes in tenomodulin expression compared to
undifferentiated ADSCs, this is likely due to the fact that tenomodulin is considered a
late-stage marker for tenocytes. Therefore, we are seeing high levels of expression of
tenomodulin from the isolated mature tenocytes, but low expression levels from the
differentiating cells. In conclusion, the static differentiation would prove to the best
inducer of a tenocyte-like expression compared to dynamic differentiation.

Figure 2.14. Potential Mesenchymal stem cells differentiation lineages.
Study 2 focused on the ideal differentiation period for inducing tenocyte-like
expression in the cells. A study done by Park et al. showed decreased expression of both
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scleraxis and tenomodulin from day 6 to day 12 in cells treated with 100ng/mL GDF-5,
but an increase in collagen I, therefore leading me to believe that a 7 day differentiation
period would be ideal [11]. Unfortunately, however tenomodulin expression was downregulated in the cells treated with BMP-12 normalized to undifferentiated tenocytes
cultured for the same duration. However, scleraxis does follow the trend seen by Park,
with increase expression at 7 days versus 14 days. This is verified by the results from
Study 3. The expression of all the genes is up-regulated at day 7 compared to day 14
when treated with BMP-12. In addition, tenocyte expression for each of the markers is
fairly low, however this does not mean these markers are not a good indicator of
tenocytes. It is believed that expression levels for tenocytes was decreased due to the fact
that the cells were directly isolated from mature tendons and the RNA was isolated
immediately. Therefore, because the cells were not cultured like the experimental groups,
they never needed to establish a comparable new extracellular matrix or tenocyte like
environment, potentially making their expression levels lower. This same trend is seen
throughout each of the studies for both AIM 1 and AIM 2. For Study 3, I also wanted to
observe the differentiation effects of TGF-β1. Originally I hypothesized that expression
of the tenocyte markers would be elevated in the group treated with the combination
media, however after the study was completed it was learned that BMP-12 is part of the
TGF-β superfamily, and therefore instead of working together to further induce tenogenic
differentitaion in the cells, it is highly possible they had more of a competitive
relationship, and therefore expression for each of the markers was decreased. In addition,
BMP-12 induced a higher expression profile of the tenocyte markers, scleraxis, collagen

86

I, and collagen III compared to TGF-β1. Studies have found that reduction in TGF-β at
injury sites is assocaited to a decrease in scar formation [12]. Therefore, when TGF-β is
present, it could be promoting more “scar formation” than tenocyte differentation,
causing expression levels to be reduced.
Study 4 was performed to determine whether there was link in gene expression
levels and the presence of protein expression in each of the experimental groups.
Unfortunately, no protein expression was seen for collagen III or scleraxis. Due to the
fact that scleraxis is a transcription factor and only present in a cell for a very short period
of time, it was believed this was why no expression was seen (because the western blot
was carried out at multiple antibody concentration and nothing was seen for any of them).
However, there is a possibility that the antibodies were not binding appropriately, which
is why I believe we see no expression of collagen III.
When comparing Study 3 data to Study 4 data, we see that there was a large
expression of collagen I gene at 7 days and hardly any expression at 14 days, however
this is not represented in the protein analysis. Protein expression levels at day 14 are
approximately half of the amount of expression seen at day 7. However tenomodulin
expression levels do seem to follow the same trend from gene expression to protein
expression within the BMP-12 differentiation group and the TGF-β1 differentaion group.
However, the combination group which shower higher gene expression at day 7 showed
higher protein expression of tenomodulin at 14. This is also the case for collagen I
expression levels in seen from the combination group. Therefore, BMP-12 and TGF-β1
showed the higher reproducibility from gene expression to protein expression, further
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verifying that these groups are more capable of inducing a tenocyte-like phenotype in the
adipose derived stem cells. Furthermore, BMP-12 seems to do this more than TGF-β1.
Lastly, the cells ability to differentiate on a scaffold was analyzed. Scleraxis,
collagen I, tenomodulin, and collagen III gene expression levels were all downregulated
when normalized to undifferentiated adipose derived stem cells cultured on monolayer.
Because previous studies showed us that differentiation on monolayer using BMP-12
induces higher expression of these genes, we can then conclude that differentiation on a
scaffold restricts differentiation into tenocytes compared to differentation on monolayer.
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CHAPTER THREE
AIM 2: EVALUATION OF THE INTRODUCTION OF DIFFERENTIATED LEWIS
RAT ADIPOSE DERIVED STEM CELLS INTO AN INDUCED INJURY SITE IN
LEWIS RAT ACHILLES TENDON
3. AIM 2:
3.1.

Introduction

Due to high re-tear rates seen in tendons and how debilitating these tears can be,
it is essential to find a method to reduce the number of re-tears. Therefore, AIM 2 focuses
on effects caused by the introduction of BMP-12 differentiated stem cells into a tendon
during repair.

3.2.

Materials

Conexa™ 200 Reconstructive Tissue Matrix (BCP 051020) was purchased from Tornier,
US. LIVE/DEAD® Viability/Cytotoxicity Assay Kit (L-3224) was purchased from
Invitrogen. ElectroForce® 3200 Series II and load cell was purchased from Bose.
Weigert’s Hematoxylin Solution (A&B set) (S216B) and Masson’s Trichrome Method
for Connective Tissue (K037) were purchased from Polyscientific. Recombinant Mouse
GDF-7/BMP-12 (779-G7) was purchased from R&D Systems. DMEM containing 1g/L
glucose (MT-10-014-CM), 1X Phosphate Buffered Saline without Ca2+ and Mg+ (MT-
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20-031-CV), BSA from Rockland – fraction V (NC9418785) and Antibiotic/Antimycotic
(MT-30-004-Cl) were purchased from Fisher Scientific.

3.3.

Methods

3.3.1. Scaffold characterization

For implantation, porcine dermis Conexa™ 200 Reconstructive Tissue Matrix
(Tornier US, BCP 051020) was chosen as the surface for cell seeding and for
implantation in the Lewis rats. Because Conexa™ is a sterile medical device, no
additional sterilization procedures were required. Conexa™ also provides an intact
extracellular matrix with glycoproteins for cells to bind to and a vascular channels
allowing for blood perfusion to the host tissue. Each scaffold was cut into 2mmx6mm
rectangles using a punch specifically manufactured for the project.

3.3.2. Adipose derived stem cell differentiation and scaffold seeding

Due to the study results from AIM 1, Lewis rat Adipose Derived Stem Cells were
seeded into T150’s and cultured with either BMP-12 differentiation media or control
media, as described in Table 3.1. Cells were allowed to differentiate on monolayer for six
days and were then trypsinized for cell counting. Due to a high cell confluence, cells
were re-suspended in collagenase after trypsinization and placed in the incubator at 37°C
for 45-60 minutes. After, the collagenase was neutralized using control media at 3x the
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volume of collagenase solution and the cells were spun down and re-suspended in the
appropriate amount of media to provide 1,000,000 cells per 9uL. Because each scaffold
was seeded with 1,000,000 of their respective cell types, 9uL was the ideal volume
because it ensured that all 1,000,000 cells were seeded and adhered to only the top of
each scaffold for two hours before additional differentiation or control media was added
for the remaining 72 hours of culturing. A total of 30 scaffold were seeded from each
study group: scaffold + undifferentiated stem cells and scaffold + BMP-12 differentiated
stem cells. After the differentiation period was completed, the samples were incorporated
into the Achilles tendon of rat.

Table 3.1: Lewis Rat Adipose Derived Stem Cell Media for In-Vivo Study
Study

Group

Basal Medium*

Serum

Supplementation

In-vivo

Control
BMP-12

DMEM
DMEM

10% FBS
10% FBS

1% antibiotic/antimycotic
1% antibiotic/antimycotic
50ng/mL BMP-12

*All basal medium contained 1g/L Glucose

3.3.3. Pre-implanted scaffold processing and histological analyses

CELL VIABILITY: LIVE/DEAD IMAGING
Live/Dead imaging was preformed on two scaffolds from each experimental
group (seeded with either undifferentiated ADSCs or BMP-12 differentiated ADSCs)
seeded for three days to ensure the cells were viable before implantation. This was
performed using the same protocol from AIM 1.
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SCAFFOLD PROCESSING
Two control Conexa™ scaffolds and two scaffolds from each experimental group
(seeded with either undifferentiated ADSCs or BMP-12 differentiated ADSCs) seeded for
three days were placed into 10% formalin for a minimum of 24 hours. The total volume
of formalin was at least four times the volume of the tissue to ensure thorough fixation.
They were then labeled according to the Accession log protocol and placed into cassettes
to be processed in the tissue processor using the protocol below. The total time to
complete tissue processing is 8 hours.

1. Place samples within their cassettes into the tissue-processing basket.
2. Run Program 1: step shown in Table 3.2 below.
3. Remove cassettes. Samples ready for embedding.
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Table 3.2: Tissue Processing Procedure
Step

Immersion Solution

Duration (min)

1
2
3
4
5
6
7
8
9
10
11
12
13
14

10% Buffered Formalin
10% Buffered Formalin
70% Ethanol
80% Ethanol
95% Ethanol
95% Ethanol
100% Ethanol
100% Ethanol
Xylene
Xylene
Paraffin
Paraffin
Paraffin
Paraffin

30
30
30
30
45
45
45
45
20
40
30
30
30
30

SCAFFOLD EMBEDDING AND SECTIONING
Processed scaffolds were embedded such that the scaffold was oriented with the
seeded side face down to obtain longitudinally 5µm sections. This was done by placing
the metal embedding tray on the hot plate and filling it with paraffin. Next, the tissue was
positioned on the bottom of the metal tray in the preferred orientation using tweezers.
While holding the tissue down, the metal tray was placed onto the cold plate briefly to
prevent the sample from moving. Then, the cassette was placed on the metal tray and the
remaining space on top of the cassette was filled with paraffin. The metal tray was then
immediately moved to the cold plate, allowing the paraffin to harden. After hardening,
the block was removed from the metal tray and stored at room temperature for sectioning.
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SCAFFOLD SECTIONING
Prior to sectioning, the water bath was heated to 40°C and coins were placed in
the bottom to capture the air bubbles floating in the water to prevent interference with the
sections. Also, the blade was replaced to ensure the sections were cut finely. After
sending the microtome’s block holder “HOME”, the block was inserted and the blade
was placed for cutting. Initially, the blocks were trimmed at 15 microns to reach the
samples within the wax, and once the appropriate depth was achieved, sections were
taken at 5 microns. After sectioning, the slides were placed in the oven overnight to
remove excess paraffin for staining.

HISTOLOGICAL ANALYSIS

HEMATOXYLIN AND EOSIN (H&E)
Processed Conexa™ scaffolds were stained with Weigert’s Hematoxylin
Solution, A&B set (Polyscientific, S216B) using the protocol below in Table 3.3. Richard
Bruner of Research Pathology Associate, LLC compared stained pre-implanted scaffolds
to H&E stained implanted scaffolds according to the protocol in the following section.
From the Hematoxylin and Eosin, the nuclei were stained blue, the erythrocytes and
eosinophilic granules were stained bright pink to red, and the cytoplasm and other tissue
elements were stained various shades of pink.

96

Table 3.3: Hematoxylin and Eosin Staining Procedure
Step

Immersion Solution

Duration

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Xylenes
Xylenes
100% Ethanol
100% Ethanol
95% Ethanol
95% Ethanol
Tap water
Distilled water
Hematoxylin
Tap water
Clarifier
Tap water
Bluing reagent
Tap water
95% Ethanol
Eosin
95% Ethanol
95% Ethanol
100% Ethanol
100% Ethanol
100% Ethanol
Xylenes
Xylenes

10 dips
5 min
10 dips
1 min
10 dips
1 min
Till “sheeting” action occurs
1 min
5 min
Till clear
4 dips
Till “sheeting” action occurs
1 min
1 min
10 dips
45 sec
10 dips
10 dips
10 dips
1 min
3 min
10 dips
5 min

MASSON’S TRICHROME
Processed Conexa™ scaffolds were stained using the Masson’s Trichrome
Methods for Connective Tissue (PolyScientific R&D Corp., k037). Richard Bruner of
Research Pathology Associate, LLC compared stained pre-implanted scaffolds to
Masson’s Trichrome stained implanted scaffolds according to the protocol in the
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following section. Collagen was represented with blue stain and keratin and muscle was
represented with red stain.

3.3.4. Animal Model

In-vivo surgeries were performed on male Lewis rat Achilles tendons by Richard
Hawkins M.D., Greg Colbath, M.D., and Theodore Schlegel M.D. Each rat was placed
into one of three study groups: Conexa™ scaffold containing no cells, Conexa™ scaffold
containing undifferentiated stem cells, and Conexa™ scaffold containing BMP-12
differentiated stem cells. Cells were seeded onto the scaffolds using the protocols from
AIM 1. Each rat (n=60) underwent an intentional window injury, as shown below in
Figure 3.1, on the right leg while the left leg, or contralateral leg, was left intact and used
as a control. After an injury was made, the window was bridged by a Conexa™ tendon
scaffold and sutured into place using non-degradable sutures to ensure durability. The
implanted scaffold type was chosen based on the study group in which the rat resided.
These scaffolds remained implanted for a total of seven weeks before Greg Colbath,
M.D. and Jonathan Kuo, Ph.D. sacrificed the rats for sample removal.
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Figure 3.1: Model of the window transection in the Achilles tendon of Lewis rats. The
transected region was discarded and the Conexa scaffold was sutured into its original
place.

3.3.5. Implanted Scaffolds

HISTOLOGICAL ANALYSIS
Four rats from each study group were sacrificed for histological analysis. The
repaired tendon containing the scaffold and healthy tendon from the contralateral leg of
each rat were removed. The boney insertion was removed completely from the tendon
while a small portion of muscle belly was left intact on the opposite end. For each rat, the
healthy and repaired tendons were labeled and stored separately in formalin filled
containers for a minimum of 48 hours. The total volume of formalin was at least four
times the volume of the tissue to ensure thorough fixation.

99

TISSUE PREPARATION
Before processing the tendon, the muscle belly was removed and the tendon was
marked with tattoo ink to maintain orientation.

TISSUE PROCESSING PROTOCOL FOR RAT ACHILLES TENDON
All samples were entered into the Accession log prior to processing. Once each
sample was placed into a respectively labeled cassette matching the Accession log, they
were processed using the protocol previously mentioned.

HEMATOXYLIN AND EOSIN STAINING
Processed control and experimental implanted Conexa™ scaffolds were stained
using the protocol above. Richard Bruner of Research Pathology Associate, LLC
compared stained pre-implanted scaffolds to H&E stained implanted scaffolds according
to the protocol in the following section. From the Hematoxylin and Eosin, the nuclei were
stained blue, the erythrocytes and eosinophilic granules were stained bright pink to red,
and the cytoplasm and other tissue elements were stained various shades of pink.

MASSON’S TRICHROME STAINING
Processed control and experimental implanted Conexa™ scaffolds were stained
using the same protocol as used for pre-implanted scaffolds. Richard Bruner of Research
Pathology Associate, LLC compared stained pre-implanted scaffolds to Masson’s
Trichrome stained implanted scaffolds according to the protocol in the following section.
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Collagen was represented with blue stain and keratin and muscle was represented with
red stain.

HISTOPATHOLOGIC EXAMINATION
Richard Bruner, an ACVP board-certified pathologist, of Research Pathology
Associate, LLC performed a histopathologic examination of 1) pre-implanted scaffolds,
2) healthy control tendons, 3) each of the three groups containing an implanted scaffold.
Samples were observed microscopically for 1) Findings along the scaffold surface, 2)
Findings within the central matrix of the scaffold, and 3) Findings associated with the
juxtaposed native Achilles tendon. Responses were grading as follows: 0 = within normal
limits, 1 = minimal, 2 = mild, 3 = minimal, 4 = marked (severe).

GENE ANALYSIS
Six rats from each study group were sacrificed for gene analysis. The repaired
tendon containing the scaffold and healthy tendon from the contralateral leg of each rat
were removed. For each rat, the healthy and repaired tendons were separated and labeled
appropriately until pooling occurred as described later. tRNA was isolated from the
tendons and analyzed using the protocols from AIM 1. Three tRNA samples were pooled
from three legs within the same group during isolation to obtain an n=2 samples for both
healthy and repaired tRNA. After rt-PCR was performed, the samples were normalized to
pre-implanted scaffolds seeded with undifferentiated stem cells and 2-ΔΔCt values were
calculated.
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MECHANICAL ANALYSIS
Ten rats from each study group were sacrificed for mechanical analysis. Each leg
was removed and cleaned of excess soft tissue, however leaving a portion of the proximal
muscle belly and a portion of the calcaneus bone to aid in testing. The leg containing the
Conexa™ repaired tendon and the healthy, contralateral leg of each rat were removed,
wrapped separately in PBS soaked gauze and aluminum foil, and frozen at -20°C until
testing took place. 24 hours prior to testing, the samples were moved to +4°C to allow
thawing. A total of 46 legs were dissected for testing: 16 control legs and 10 legs from
each implantation group. Mechanical testing was performed on the ElectroForce® 3200
Series II with a 100lbf load cell (Bose). Prior to inserting the samples into the Bose, the
width and thickness of the samples were measured four times and averaged to determine
to initial cross-sectional area. Samples were placed vertically into the clamps in such a
way to ensure only the tendon was being mechanically tested. Tendon orientation can be
seen below in Figure 3.2. For tensile testing, a 2N preload was then applied and the L0
was measured in mm. All measurements were made with a slide caliper. The tendon was
then loaded at a rate of 10mm/min and the location of failure was noted. [1] The
structural properties of the tendon and tendon-scaffold complex were then calculated.
This included linear stiffness, yield, or ultimate deformation, ultimate load, failure stress,
and failure strain. Linear stiffness was measured by taking the slope of the Force (N) vs.
displacement (m) graph from initial load to failure. This was done for each sample and
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averaged. The mechanical properties of different treatment groups were compared using
the Student t test and the level of significance was set at p < 0.05. [1]

Figure 3.2: Bose mechanical testing setup used to test the load to failure in rat Achilles
tendons. The tendon, shown in pink, is placed between the grip and a load is applied
vertically.
TISSUE CLAMPS
Clamps were designed to grip the tissue firmly, preventing slipping during testing,
without the use of dry ice. Clemson Machining and Technical Services manufactured the
grips, which can be seen below in Figure 3.3.
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Figure 3.3: Tissue Clamps designed for mechanical testing.
3.4.

Results

3.4.1. Seeding viability on scaffolds

Scaffolds seeded with undifferentiated Adipose Derived Stem Cells or BMP-12
differentiated cells were stained with a LIVE/DEAD® Viability/Cytotoxicity Assay Kit in
order to determine cell viability before implantation. Representative images were taken
and shown in Figure 3.4 below. No dead cells were observed, however the scaffold does
auto-fluoresce red.
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B) BMP‐12 DIFFERENTIATED
ADSC SEEDED SCAFFOLD

A) UNDIFFERENTIATED
ADSC SEEDED SCAFFOLD

Figure 3.4: Cell viability of A) Undifferentiated ADSCs seeded onto Conexa scaffold or
B) BMP-12 differentiated ADSCs seeded onto Conexa for a total of 72 hours after being
cultured on monolayer. Live cells are depicted in green and dead cells are depicted in
red.

3.4.2. Histological analysis

HEMATOXYLIN AND EOSIN
Pre-implanted scaffolds seeded with undifferentiated Adipose Derived Stem Cells
(A) or BMP-12 differentiated cells (B) were stained with Hematoxylin and Eosin (H&E),
as seen in Figure 3.5. Similar scaffolds implanted into the Achilles tendon were removed
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after seven weeks and were also stained with H&E. The study groups include A) healthy,
non-injured tendon, B) tendon mended with an unseeded Conexa scaffold, C) tendon
mended with an undifferentiated ADSC seeded Conexa scaffold, and D) tendon mended
with a BMP-12 differentiated ADSC seeded Conexa scaffold. These images can be seen
below in Figure 3.6.

Figure 3.5: Hematoxylin and Eosin staining of pre-implanted Conexa scaffolds seeded
with A) Undifferentiated ADSCs or B) BMP-12 differentiated for a total of 72 hours after
being cultured on monolayer. The extracellular matrix is represented with pink stain and
the cell nuclei are represented with purple stain.
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A)#TENDON#
CONTROL#

B)#IMPLANTED#
SCAFFOLD#with#
no#cells#

4"

C)#IMPLANTED#
SCAFFOLD#
with#
undiﬀeren@ated#
ADSCs#

D)#IMPLANTED#
SCAFFOLD#
With#BMPC12#
diﬀeren@ated#
ADSCs#

Figure 3.6: Hematoxylin and Eosin staining of A) healthy control tendons, or repaired
tendon containing a Conexa scaffold seeded with B) No cells, C) Undifferentiated ADSCs
or D) BMP-12 differentiated ADSCs. Scaffolds were implanted for a total of seven weeks.
The extracellular matrix is represented with pink stain and the cell nuclei are represented
with purple stain.

MASSON’S TRICHROME
Pre-implanted scaffolds seeded with A) no cells, B) undifferentiated Adipose
Derived Stem Cells, or C) BMP-12 differentiated cells were stained with Masson’s
Trichrome (MT), as seen in Figure 3.7. Similar scaffolds implanted into the Achilles
tendon were removed after seven weeks and were also stained with MT. The study
groups include A) healthy, non-injured tendon, B) tendon mended with an unseeded
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Conexa scaffold, C) tendon mended with an undifferentiated ADSC seeded Conexa
scaffold, and D) tendon mended with a BMP-12 differentiated ADSC seeded Conexa
scaffold. These images can be seen below in Figure 3.8.

Figure 3.7: Masson’s Trichrome staining of pre-implanted Conexa scaffolds seeded with
A) No cells, B) Undifferentiated ADSCs, or C) BMP-12 differentiated for a total of 72
hours after being cultured on monolayer. Collagen is represented with blue stain and
keratin is represented with red stain.
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A)#IMPLANTED#
SCAFFOLD#with#
no#cells#

B)#IMPLANTED#
SCAFFOLD#
with#
undiﬀeren?ated#
ADSCs#

C)#IMPLANTED#
SCAFFOLD#
With#BMPB12#
diﬀeren?ated#
ADSCs#

Figure 3.8: Masson’s Trichrome staining of A) healthy control tendons, repaired tendon
containing a Conexa scaffolds seeded with B) No cells, C) Undifferentiated ADSCs or D)
BMP-12 differentiated ADSCs. Scaffolds were implanted for a total of seven weeks.
Collagen is represented with blue stain and both keratin and muscle are represented with
red stain.

HISTOPATHOLOGIC EVALUATION
Samples underwent a histopathologic evaluation and were scored according to the
above protocol. Samples scores can be found below. Pre-implanted scaffold scores can be
found in Table 3.4. Samples taken from the control, healthy legs of rats after the duration
of the animal study can be found below in Table 3.5. Scores evaluating the implanted
scaffolds containing no cells, undifferentiated ADSCs, or BMP-12 differentiated ADSCs
and their surround tendon can be found in Table 3.6, Table 3.7, and Table 3.8,
respectively.
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Table 3.4: Histopathologic Examination Scores: Pre-implanted Scaffolds
Unseeded

Seeded with
Undifferentiated
ADSCs

Seeded with BMP12 Differentiated
ADSCs

Scaffold Surface (n=2)
Undifferentiated cells
Spindle Cells
Macrophages
Lymphocytes
Plasma cells
Neutrophils
Adipose cells
Neovascularity

0,0
0,0
0,0
0,0
0,0
0,0
0,0
0,0

2,0
1,0
0,0
0,0
0,0
0,0
0,0
0,0

0,0
0,1
0,0
0,0
0,0
0,0
0,0
0,0

Scaffold Matrix (n=2)
Undifferentiated cells
Spindle Cells
Macrophages
Lymphocytes
Plasma cells
Neutrophils
Adipose cells
Neovascularity

0,0
0,0
0,0
0,0
0,0
0,0
0,0
0,0

0,0
0,0
0,0
0,0
0,0
0,0
0,0
0,0

0,0
0,1
0,0
0,0
0,0
0,0
0,0
0,0

Evaluation Region

Table 3.5: Histopathologic Examination Scores: Control Tendon
Evaluation Region
Juxtaposed Tendon (n=11)
Chondro-osseous metaplasia
Undifferentiated cells
Fibrosis/Fibroplasia
Adipose cells
Neovascularity

# of 0s

# of 1s

9
11
11

2
1

11
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# of 2s

10

# of 3s

# of 4s

Table 3.6: Histopathologic Examination Scores: Unseeded Scaffold Implants
Evaluation Region
Scaffold Surface (n=2)
Undifferentiated cells
Spindle Cells
Macrophages
Lymphocytes
Plasma cells
Neutrophils
Adipose cells
Neovascularity

# of 0s

# of 1s

# of 2s

# of 3s

# of 4s

2
2
2
2
2
2
2

Scaffold Matrix (n=2)
Undifferentiated cells
Spindle Cells
Macrophages
Lymphocytes
Plasma cells
Neutrophils
Adipose cells
Neovascularity

2
1
2
2
2
2

Juxtaposed Tendon (n=4)
Chondro-osseous metaplasia
Undifferentiated cells
Fibrosis/Fibroplasia
Adipose cells
Neovascularity

1
1
1
3
3

1

1
1

1

1

1

1
3
3

1
1
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1

Table 3.7: Histopathologic Examination Scores: Undifferentiated ADSC
Seeded Scaffold Implants
Evaluation Region
Scaffold Surface (n=2)
Undifferentiated cells
Spindle Cells
Macrophages
Lymphocytes
Plasma cells
Neutrophils
Adipose cells
Neovascularity

# of 0s

# of 1s

# of 2s

# of 3s

# of 4s

1
1

1

1
2
2
2
2
1

Scaffold Matrix (n=2)
Undifferentiated cells
Spindle Cells
Macrophages
Lymphocytes
Plasma cells
Neutrophils
Adipose cells
Neovascularity

2
2
2
2
2
2

Juxtaposed Tendon (n=3)
Chondro-osseous metaplasia
Undifferentiated cells
Fibrosis/Fibroplasia
Adipose cells
Neovascularity

1
2
1
2
2
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1
1

1
2

1

1
1
1

1
1
1

Table 3.8: Histopathologic Examination Scores: BMP-12 Differentiated
ADSC Seeded Scaffold Implants
Evaluation Region
Scaffold Surface (n=4)
Undifferentiated cells
Spindle Cells
Macrophages
Lymphocytes
Plasma cells
Neutrophils
Adipose cells
Neovascularity
Scaffold Matrix (n=4)
Undifferentiated cells
Spindle Cells
Macrophages
Lymphocytes
Plasma cells
Neutrophils
Adipose cells
Neovascularity
Juxtaposed Tendon (n=4)
Chondro-osseous metaplasia
Undifferentiated cells
Fibrosis/Fibroplasia
Adipose cells
Neovascularity

# of 0s

# of 1s

# of 2s

1

4
3

1
4
4
4
3

2

1

2

1
2

4
3
4
4
4
3

# of 3s

# of 4s

1
1
2
1

1
2

1

3

1
1

4
4
2

1

1

Results showed that implant groups (scaffold only, scaffold seeded with
undifferentiated stem cells, and scaffold seeded with BMP-12 differentiated stem cells)
were very similar. Overall, there was a high presence of mononuclear cells with pale
staining cytoplasm. This is a characteristic prevalent in differentiating stem cells,
macrophages, and even possibly fibroblasts or synovial cells. In terms of the scaffold
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implantation groups, there was a population of spindle cells that aligned along the
collagen bundles within the scaffold and along the surface, which can be seen below in
A) of Figure 3.9. These cells possessed dark staining and according to the histopathologic
report, these cells have the potential to differentiate into mature fibrocytes or tenocytes.
Despite their presence, however, there was no distinct fibrous capsule surrounding the
scaffold. This is promising because the presence of a fibrous capsule is typically a feature
seen around implants undergoing host rejection. In addition, there was a general absence
of plasma cells, which are found in regions with antigenic presence. Although this is the
case, there was still a high prevalence of inflammatory cells indicating the scaffold may
have been acting as a foreign body irritant. This can be seen below in B) of Figure 3.9. It
is possible the scaffold was jagged and therefore irritating the surrounding regions. In
addition, the cells may have been present due to the surgical damage that occurred to the
native Achilles tendon. Interestingly, where the image is labeled *, you can see that the
scaffold has either fully integrate with the tendon in this region, or the cells have
remodeled the scaffold into a tendon-like composition. Lastly, in the rats that underwent
scaffold implantation, there was a prevalence of chondro-osseous metaplasia in the native
surrounding tendon, as seen in C) of Figure 3.9. This was characterized by the presence
of chondrocytes undergoing mineral deposition within the tendon. However, this focal
deposition of minerals was only seen in two of the 11 control tendons.
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A)

B)

*"

C)

Figure 3.9: Hematoxylin and Eosin staining of A) cells infiltrating the scaffold matrix of
tendon implanted with a scaffold seeded in undifferentiated ADSCs, B) an inflammatory
response around an implanted scaffold containing BMP-12 differentiated ADSCs, and C)
chondro-osseous metaplasia occurring within the tendon implanted with a scaffold
containing no seeded cells.
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3.4.3. Gene Analysis

Healthy tendons and tendons containing implanted scaffolds were removed from
the three experimental groups of the animal study. In conjunction with these groups,
RNA was isolated and quantified from pre-implanted scaffolds seeded with either
undifferentiated ADSCs or BMP-12 differentiated ADSCs. These values were
normalized to pre-implanted scaffolds seeded with undifferentiated ADSCs. As the
graphs show in Figure 3.10, scleraxis expression is statistically reduced in each of the
experimental groups compared to healthy tendon, however there are no statistical
differences in expression levels between the experimental groups. To note, implanted
scaffolds containing BMP-12 differentiated ADSCs are the only group whose scleraxis
expression levels were not significantly reduced compared to the healthy tendon.
Tenomodulin expression was statistically higher in the group containing a
scaffold seeded with undifferentiated ADSCs compared to healthy tendons. This group
and the group containing a scaffold seeded with BMP-12 differentiated cells also express
tenomodulin significantly higher than pre-implanted scaffolds containing BMP-12
differentiated cells. The implant groups containing either undifferentiated stem cells,
BMP-12 differentiated ADSCs, or no cells also express collagen I significantly higher
pre-implanted scaffolds containing BMP-12 differentiated ADSCs. However, implants
with undifferentiated ADSCs also express more collagen I and collagen III than healthy
tendon.
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Figure 3.10: Pre-implanted scaffolds, implanted scaffolds, and healthy tendon expression
levels of A) Scleraxis, B) Tenomodulin, C) Collagen I, and D) Collagen III normalized to
pre-implanted scaffolds seeded with undifferentiated ADSCs (n=3). Standard error bars
are present. Connecting horizontal bars represent statistical differences (p<0.05).
3.4.4. Mechanical Analysis

The average ultimate load, the ultimate load range, the average ultimate
deformation, the average failure stress, the average failure strain, and the average
stiffness were calculated for each experimental group and are shown in Table 3.9 below.
With respect to the average ultimate load, there was no statistical difference between any
of the four groups. Similarly, there was no statistical difference between any two groups
with respect to average ultimate deformation. There was a statistical difference in the
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failure stress between the control group and the three remaining experimental groups:
scaffold only (p<0.0001), scaffold seeded with undifferentiated ADSCs (p<0.0001), and
scaffold seeded with BMP-12 differentiated ADSCs (p<0.0001). However, there were no
statistical differences between these three groups. Finally, there was statistical difference
in the average failure strain between the control group and the group implanted with
scaffolds seeded with undifferentiated ADSCs (p=0.0489) and between the control group
and the group implanted with scaffold seeded with BMP-12 differentiated ADSCs
(p=0.0439). There were no statistical differences between the group implanted with
unseeded scaffolds and the other three experimental groups.

Table 3.9: Mechanical testing results

Study Group

Control Achilles
tendon
Achilles tendon
with unseeded
scaffold
Achilles tendon
with
undifferentiated
ADSC seeded
scaffold
Achilles tendon
with BMP-12
differentiated
ADSC seeded
scaffold

Average
Ultimate
Load
(N)

Ultimate
Load
Range
(N)

Average
Ultimate
Deformation
(m)

Average
Failure
Stress
(MPa)

Average
Failure
Strain
(%)

Average
Stiffness
(N/m)

57.18

37.97 to
84.20

0.00273

3.96

55.42

0.6169

48.73

30.16 to
71.94

0.00280

1.00

43.69

0.3129

51.74

33.70 to
72.25

0.00292

1.44

35.95

0.6456

50.97

32.78 to
67.99

0.00298

1.16

35.46

0.3179
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3.5.

Discussion

Mechanical data showed that there were no statistical differences between the
average failure stresses of the three experimental groups, however the control tendon was
stronger. Unfortunately, this means the scaffold is either masking the effects of the cells
due to its composition, or the cells are having no effect on the tendon healing. In addition,
the control tendons were capable of elongating a further distance before failure than the
groups containing the scaffolds with seeded cells. However, there are again no
differences between the experimental group implying the scaffolds either masked the
effects of the cells of the cells had no effect.
Gene analysis showed similar results in that healthy tendons expressed higher
levels of scleraxis mRNA transcript than the experimental groups, but there we no
differences between the experimental groups. However, collagen III, tenomodulin, and
collagen I expression was up-regulated in the group containing scaffolds seeded with
undifferentiated adipose derived stem cells compared to the healthy tendon. This could be
due to the immune suppressing effects caused by undifferentiated adipose derived stem
cells. Because the stem cells are slightly suppressing the immune response caused by
scaffold, it allows us to see the effects of the native cells trying to heal the region by
secreting collagen I, III, and tenomodulin. Overall however, it is hard to differentiate the
effect of the implanted cells due to the presence of the matrix and the fact that native
tendon was also taken out of the rat with the scaffolds and analyzed, which may be
masking the results of the cells.
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Based on the Live/Dead analysis performed on pre-implanted scaffolds, we see
that the cells are alive and covering the surface of the scaffold. However, from H&E and
MT histology, this is not prevalent. One reason this may be the case is because the
scaffold was so dense, the cells did not have enough time to migrate into the scaffold
prior to implantation. Therefore, when sections were taken, all the cells were on the top
surface and may have gotten removed from the block during trimming. From the H&E
we also see that there is a large population of inflammatory cells surrounding the
scaffolds, including in the group implanted with a scaffold and no cells. In addition, no
foreign body giant cells or plasma cells are surrounding the scaffolds in any of the
groups, leading me to believe that the scaffolds are acting as an irritant instead of an
antigen. These cells could also be present due to the cytokines released from the tissue
damaged from the transection. Despite why the cells are present, it is important to note
that the density of inflammatory cells within each implantation group remains consistent
and you do not see a reduced immune response in the group implanted with a scaffold
seeded with undifferentiated stem cells. However, is it important to note that implantation
of scaffolds seeded with BMP-12 differentiated cells appears to be either fully integrating
into the tendon, as depicted by the * in Figure 3.9, or the infiltrating cells have remodeled
this region completely to resemble a tendon structure.
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CHAPTER FOUR
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK
AIM 1: Studies have shown that differentiation of adipose derived stem cells isolated
from the inguinal fat pads of Lewis rats are multipotent and capable of differentiating into
tenocytes. Studies showed that cells cultured on monolayer for a total of 7 days in BMP12 differentiation media induced the most tenocyte-like phenotype in the cells.

However, in order to more accurately say this, gene studies should be reanalyzed
compared to tRNA isolated from tenocytes that underwent cells culture, instead of tRNA
that was directly isolated from extracted tendon. This would be a more similar
comparison between the tenocytes and cell differentiated for 7 or 14 days because each
cell type would have to produce an extracellular matrix, which may have increased
expression for each of our markers in our tenocyte group. However, this would not have
changed the trends seen between the experimental groups considering all expression
levels were normalized to undifferentiated ADSCs cultured for the same duration of time
as the cells undergoing differentiation.
Secondly, a differentiation study should be performed comparing cells seeded on
monolayer and cells seeded on the selected implantation scaffold type. Due to the fact
that the scaffold type was changed from decellularized porcine pericardium after AIM 1
was completed, we do not know whether the cells were able to undergo differentiation
upon the Conexa scaffold, despite its similar composition.
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AIM 2: Studies have shown that the effect of the implanted cells is masked
mechanically, molecularly, and histologically by the presence of the Conexa graft.
However, integration of the graft or remodeling of the graft to resemble tendon is seen in
the group containing implants seeded with BMP-12 undifferentiated stem cells.

For future studies, a graft that is capable of being fully remodeled by cells by the
end of the study period is necessary to see the full effects of the stem cells. One
possibility would be decellularized porcine pericardium. Another option would be to use
fibrin as a cell carrier because it would be completely dissolved by the end of the study
period and would allow us to analyze only the effects of the stem cells. Secondly, the
animal model for the next study should be larger, and the seeding of the scaffold and its
insertion should be performed differently. To be able to fully understand the histological
analysis, it would be beneficial to perform cell tracking on the implanted cells to see
where they end up, if they’re still alive, if they have continued to differentiate, or if
they’re proliferating.
In addition, during mechanical testing, because there was only a window
transection performed versus a full transection of the tendon at the time of surgery, it was
impossible to determine whether the mechanical data was measuring the strength of the
tendon due to the implanted cells/scaffold or the strength of the surrounding healthy
tendon that was fully intact from insertion to origin. For this study, the tendon and
scaffold worked as a composite, masking the effects of the stem cells. Next time, a full
transection should be performed to determine the sole effects of the stem cells.
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Furthermore, when samples are taken for molecular analysis, it is critical that the scaffold
be excised from the surrounding tendon as much as possible to ensure the native tendon
isn’t masking the molecular expression of the cells embedded in the scaffold.
However, studies to be done in the short-term would include
Immunohistochemistry of the histological sections for macrophages, tenomodulin,
collagen III, and scleraxis to determine its presence in the scaffold. Performing IHC for
macrophages will allow is to characterize the inflammatory response and the three other
markers may allow us to determine any differences between the three implanted groups.
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